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MOLECULAR MECHANISMS REGULATING MYC AND PGC1β EXPRESSION IN
COLON CANCER
Jamie L. McCall, Ph.D.
University of Nebraska, 2016
Supervisor: Robert E. Lewis, Ph.D.
Identification and characterization of pathways specific to tumor cell survival, but
absent in normal tissues, provide opportunities to develop effective cancer therapies with
reduced toxicity to the patient. Kinase suppressor of Ras 1 (KSR1) is required for the
survival of colorectal cancer (CRC) cells, but dispensable in normal cells. Using KSR1
as a reference standard, we identified EPH (erythropoietin-producing hepatocellular
carcinoma) receptor (EPHB4) as a KSR1 functional analog.
We show here that, like KSR1, EPHB4 is aberrantly overexpressed in human
CRC cells and selectively required for their survival. Both KSR1 and EPHB4 support
tumor cell survival by promoting the expression of downstream targets Myc and the
transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator
1β (PGC1β). While KSR1 promotes the aberrant expression of Myc and PGC1β protein
via a post-transcriptional mechanism, EPHB4 has a greater effect on Myc and PGC1β
expression due to its ability to also elevate mRNA levels. Subsequent analysis of the
post-transcriptional regulation demonstrates that KSR1 promotes the translation of Myc.
These findings reveal novel KSR1- and EPHB4-dependent signaling pathways
supporting the survival of CRC cells through regulation of Myc and PGC1β, suggesting
that inhibition of these pathways should be selectively toxic to colorectal tumors.
We demonstrate that MEK inhibition reduced expression of Myc and PGC1β in
CRC cells. To define the pathways that regulate expression of Myc and PGC1β, we
examined the downstream effects of MEK1/2 substrates ERK1/2 and HSF1. Depletion of
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HSF1 increases Myc and PGC1β expression, while ERK1/2 inhibition decreases their
expression.
The data presented here define multiple mechanisms regulating Myc and PGC1β
expression, suggesting that tight regulation of this pathway is critical in normal cells.
Aberrant expression of Myc and PGC1β contributes to the proliferation and survival of
breast and renal cell carcinomas. We show that this pathway is also critical for CRC
survival and is ERK-dependent. Together, these data reveal that tumor cells in various
cancers require Myc-dependent expression of PGC1β to promote cell survival, which
may be exploited in the development of new cancer therapeutics.
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Ras signaling
Discovery of ras oncogenes
Ras was originally identified due to the transforming properties of the rat-derived
Harvey and Kirsten murine sarcoma retroviruses (1-3). The cellular homologs of the viral
Harvey and Kirsten ras sequences were first identified in the rat genome in 1981 (4), and
were subsequently identified in mouse (5) and human genomes (6). The Harvey
sarcoma virus-associated oncogene was named H-ras and the Kirsten sarcoma virus
form was termed K-ras in mammals. It was soon identified that human tumors often
contained mutated and constitutively activated forms of Ras proteins, including cancer
cells of bladder, colon, and lung origin (7-10). A third ras-related gene was cloned from
neuroblastoma and leukemia cell lines in 1983, it was termed N-ras (11-14).
Meanwhile, much work was focused on determining how the oncogenes differed
from the wild-type alleles. Point mutations found predominantly in codon 12, but also
less commonly in codons 13 and 61, resulted in amino acid substitutions in the encoded
Ras proteins (15-18). The characterization of ras as a true oncogene was questioned
when it was discovered that H-ras alone could not transform freshly isolated rodent
embryonic cells, but it was subsequently shown that H-RasG12V could transform primary
cells that had been previously immortalized with carcinogens (19) or transfected with
myc, SV40 large T antigen, or adenovirus E1A oncogene (20, 21). These findings
suggested that Ras proteins can only transform cells that have undergone predisposing
changes, such as acquisition of indefinite proliferation in culture (22-24). The
identification of ras mutations in patient tumors, but not normal tissue, was an important
validation that the ras mutations identified in cell lines were not merely artifacts of cell
culture (25-27).
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Approximately 30% of all human tumors screened carry a mutation in one of the
canonical ras genes (K-ras, H-ras, N-ras) (28). Mutations in ras genes predominantly
affect the K-ras locus, with oncogenic ras mutations being detected in 20-25% of all
tumors samples screened, whereas the rates for H-ras and N-ras are 3% and 8%,
respectively (28). Further analyses have shown that there are specific mutations that
correlate with certain cancer types, for example K-ras mutations are present in a majority
of pancreatic ductal adenocarcinomas and a large percentage of lung and colon tumors,
but they occur rarely in bladder cancers where H-ras is the most frequently mutated
isoform (28, 29). Additionally, N-ras mutations are frequently identified in hematopoietic
tumors and malignant melanomas, whereas K-ras and H-ras mutations in melanomas
are rare (28). H-ras mutations are the least frequent, but are prevalent in bladder
cancers (28). K-ras has two alternative splice variants that result from differential splicing
at exon 4, K-Ras4A and K-Ras4B (30, 31). Recent work in colorectal cancer has
demonstrated that K-Ras4A is associated with better overall survival, while K-Ras4B is
associated with significantly larger tumor size (32).
Interestingly, oncogenic hotspots are concentrated around two codons of the
primary nucleotide sequence of all ras family members, these include codons 12 and 61.
However, the frequency of mutations at each site varies among the three main ras family
members. Approximately 99% of the detected K-ras mutations occur at glycine 12 (G12,
86%) and glycine 13 (G13, 13%), whereas the remaining 1% occur at glutamic acid 61
(Q61) (28). Oncogenic mutations in N-ras genes have the highest rate of mutations at
Q61 (60%), and lower rates at codons 12 (24.4%) and 13 (12.7%) (28). Finally, H-ras
has another pattern of mutations, with the highest percentages detected in codon 12
(54%), followed by codon 61 (34.5%), and then codon 13 (9%) (28). While early reports
described ras amplification in some tumors and cell lines (33-35), more recent reports
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suggest that ras amplification is not a predictive marker of tumor aggressiveness (36,
37).

Activation
Heterotrimeric G proteins toggle between inactive GDP-bound and active GTPbound states (38, 39). H-ras was initially described to bind guanine nucleotides,
suggesting that it may possess intrinsic GTP hydrolysis (or GTPase) activity (40, 41) that
turned off active signaling. In 1984, three groups reported that mutated Ras
oncoproteins differed functionally from the normal counterparts in that they had impaired
GTPase activity (42-44). These studies suggested that Ras proteins were consistently in
an active state and, therefore, may promote continual downstream signaling. However,
the extent of GTPase impairment did not always correlate with transformation indicating
that it was necessary, but not sufficient, to drive aberrant Ras activation (45, 46). The
first inactivators of Ras signaling were found to possess GTPase-promoting functions
that preferentially acted upon normal, but not oncogenic N-Ras and H-Ras (43, 47, 48).
Inactivators, such as son of sevenless (SOS) and neurofibromin-1 (NF-1), were named
guanine nucleotide exchange factors (GEFs).
Oncogenic Ras mutants have impaired ability to hydrolyze GTP, either
intrinsically or in response to GTPase activating proteins (GAPs). The oncogenic
mutations at residues G12, G13, and Q61 are located in the N-terminal lobe of the Ras
catalytic site (49). When Ras interacts with GAPs, the GAP contains an arginine finger
that inserts into the Ras active site and provides a positive charge to stabilize the
negative charges that accumulate during hydrolysis (50). Normally, the arginine finger
interacts with G12. Thus, mutations at this residue inhibit the proper transition state
complex with GAPs resulting in decreased rates of hydrolysis (51). It is thought that the
increased side-chain in G13 mutations would interrupt this transition state as well. GAPs
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also increase hydrolysis by ordering the Ras active site, specifically placing Q61 in the
active site (52). In the active site, the larger Q61 forms hydrogen bonds with both the
GAP arginine finger and a water molecule (52). Substitutions at Q61 are unable to form
these dual hydrogen bonds reducing overall rates of hydrolysis.
Importantly, all Ras isoforms share amino acid sequence identity in all of the
regions responsible for GDP/GTP binding, GTPase activity, and effector interactions.
However, another key determinant of Ras transformational activity is the posttranslational lipid processing that localizes Ras to the cell membrane (53-56). The
molecular mechanism of Ras lipid processing is a stepwise progression, the first of
which is the addition of a farnesyl isoprenoid lipid to the C-terminal CAAX motif of Ras
(Fig 1.1) (57-59). This reaction is catalyzed by the enzyme farnesyl transferase (FTase).
Subsequent studies showed that this prenylation reaction is followed by proteolytic
cleavage of the AAX sequence by Ras-converting enzyme-1 (RCE1) and the
carboxymethylation of the terminal cysteine residue by the enzyme isoprenylcysteine
carboxymethyltransferase-1 (ICMT1) (60, 61). These modifications at the CAAX motif
appear to be essential for Ras association with the plasma membrane, but additional
modifications are necessary for full membrane recruitment. The C-terminal lysine
residues of K-Ras4B are sufficient to anchor it to the plasma membrane, but H-, N-, and
K-Ras4A need an additional palmitoylation step, catalyzed by palmitoyltransferase
(PTase), which adds a palmitoyl group to the C-terminus upstream of the cysteine
residue (61). The modification by farnesyltransferase occurs in the endoplasmic
reticulum (ER), whereas the palmitoylation step occurs after shuttling through the Golgi
apparatus.
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Fig 1.1 C-terminal processing of Ras.
Lipidation of the C-terminus of H-Ras, N-Ras, K-Ras4A, and K-Ras4B is necessary for
membrane targeting. First, FTase catalyzes the addition of a farnesyl pyrophosphate
group. The modified Ras is translocated to the endoplasmic reticulum where the AAX
group is cleaved by RCE) and a methyl group is added by ICMT1. At this point, K-Ras4B
can be translocated to the plasma membrane. However, H-Ras, N-Ras, and K-Ras4A
are shuttled to the Golgi where PTase adds a palmitoyl group before they are
transported to the plasma membrane.
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Epidermal growth factor (EGF) stimulation was the first identified upstream driver
of Ras activation (62). Antibodies against Ras block serum-stimulated growth in NIH-3T3
cells (63) and growth factor-induced differentiation in PC12 cells (64). Ligand stimulation
of EGF receptor (EGFR) or platelet-derived growth factor receptor (PDGFR) was found
to transiently induce GTP-bound Ras in mammalian cells (65, 66). It was therefore
hypothesized that Ras activation was required for signaling by extracellular mitogens.
Ras isoforms are preferentially expressed and activated in different tissues (67).
Additionally, it is now appreciated that there are distinct functions of Ras isoforms in
development. K-Ras4B, but not K-Ras4A, is necessary for embryogenesis (68, 69). HRas and N-Ras are not necessary for normal development, as animals lacking these
genes are viable and develop normally (70, 71). More recent work suggests that H-Ras
can functionally replace K-Ras during embryogenesis, but only when driven by the K-ras
promoter (72). This suggests that there is functional redundancy among the proteins, but
that tissue-specific expression is a necessary regulator during development.

Downstream signaling
Ligand-induced receptor tyrosine kinase (RTK) dimerization promotes
autophosphorylation in trans resulting in receptor activation (73). These phosphorylation
sites serve as binding sites for proteins that contain a Src homology 2 (SH2) domain, a
phosphotyrosine binding domain (PTB), or both, as is expressed in Shc (73, 74). Shc
then recruits Grb2 (growth factor receptor-bound protein 2) and SOS1/2 leading to Ras
activation (73). Ras-dependent signaling regulates many cellular functions including
gene expression, proliferation, survival, differentiation, cell cycle entry, and cytoskeletal
dynamics. Dysregulation of these cellular functions is a hallmark of cancer (75).
At least seven families of proteins have been shown to interact with Ras in a
GTP-dependent fashion (76, 77) (Fig 1.2). C-RAF (RAF-1) was the first known Ras
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effector (78-83). RAF is the first kinase in the RAF/MEK/ERK signaling cascade (see
below). The p110 catalytic subunits of phosphoinositide 3-kinase (PI3K) were
recognized as the second class of validated Ras effectors (84). The p110 catalytic
domain and AKT (also known as protein kinase B, a key downstream target of PI3K)
were identified independently as retroviral oncogenes (77). Additionally, knock-in mice
homozygous for a PI3K p110α lacking a Ras-binding domain (RBD) are resistant to lung
tumors induced by oncogenic K-Ras4B (85). The presence of an RBD is a common
feature of Ras effectors. Ral-specific GEFs were identified by screening for proteins with
RBDs in the C-terminal ends (86-88). Initial studies in NIH-3T3 cells suggested that
RalGEFs and their substrates, RalA and RalB small GTPases, played minor roles in
cellular transformation (89, 90). However, studies in human cells suggested that
RalGEF-Ral interactions are important in cancers of the pancreas, prostate, and bladder
(91, 92).
Less well-known effectors of Ras signaling include TIAM1 (T lymphoma invasion
and metastasis-inducing 1), PLCε (phospholipase Cε), and Nore1. TIAM1 is a Racspecific GEF that was identified in silico by searching for novel proteins with RBDs (93).
TIAM1-Rac signaling regulates the actin cytoskeleton and activates PAK (p21-activated
kinases) and JNK (c-Jun N-terminal kinase). PLCε is a novel isoform of PLC that
contains an RBD. It connects Ras signaling to the production of secondary messengers,
diacylglycerol (DAG) and calcium (94). In a carcinogen-induced mouse model of skin
cancer, TIAM1 or PLCε disruption prevented H-Ras-driven oncogenesis (95, 96).
Finally, members of the RASSF (Ras-associated domain family) family were
found to contain RBDs and mediate Ras-induced apoptosis (97, 98). RASSF5 (Nore1)
was first identified in a yeast two-hybrid assay as an effector of H-Ras (99). When Nore1
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Fig 1.2 Ras signaling pathways in mammalian cells.
Phosphorylated RTKs serve as docking sites for Shc, Grb2, and SOS1/2 (RasGEF) to
activate Ras. GTP-bound Ras activates several pathways, of which several are depicted
here. The two best studied pathways are the PI3K-AKT and the RAF/MEK/ERK kinase
cascade leading to increased survival and proliferation. RalGEFs promote the activation
of small GTPases, RalA and RalB. Activation of TIAM1, PLCε, and RASSF (Nore1)
contribute to cytoskeleton rearrangement, secondary messenger signaling, and
apoptosis, respectively.
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complexes with Mst1 (Macrophage stimulating 1), it results in a Ras-dependent, proapoptotic pathway (97). Subsequent studies indicated that RASSF1, RASSF2, RASSF4,
and RASSF6 can also play pro-apoptotic roles (100-103). This is consistent with the
observation that RASSF proteins are often downregulated in cancer cells (98).

Ras/RAF/MEK/ERK
There are three main components of the RAF/MEK/ERK signaling pathway;
however, there are several isoforms of each. The RAF family consists of C-RAF, B-RAF,
and A-RAF. MEK and ERK each have 2 members that regulate this pathway, MEK1/2
and ERK1/2, respectively. RAF, MEK, and ERK isoforms can each form dimers that
further define the specificity of signaling (104, 105).
All three paralogs of RAF contain three conserved regions: the N-terminal CR1,
which contains the RBD and cysteine-rich domain (CRD); the CR2, which contains
important residues for RAF membrane recruitment during activation; and the CR3, which
contains the kinase domain (106). Each RAF isoform appears to have a distinct
mechanism of activation, with B-RAF considered to be more active than C-RAF or ARAF (107-109). Mutations in B-RAF are commonly found in cancers, including
melanomas, but mutations in C-RAF and A-RAF are rare (110, 111). Upon growth factor
stimulation, activated Ras recruits RAF to the membrane and promotes the formation of
functionally asymmetric RAF homo- and heterodimers in which one monomer, typically,
B-RAF, allosterically stimulates the kinase activity of the other (106, 112, 113). In fact,
kinase-dead forms of B-RAF occur in human cancers and are oncogenic (114, 115).
This is due to their ability to dimerize with wild-type C-RAF and subsequently activate
MEK1/2 and ERK1/2 signaling (116).
RAF phosphorylates and activates MEK1/2 at Ser217 and Ser221, which are
located in the activation loop of MEK (117). MEKs can be partially activated by
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phosphorylation at either site, and substitution of these sites with acidic residues
enhances basal activity (118). Different RAF isoforms activate MEK1 and MEK2
differentially: A-RAF is a weak activator; B-RAF preferentially activates MEK1; and CRAF efficiently activates both MEKs (119). mek2-/- mice are viable, fertile, and show no
phenotypic abnormalities (120). Conversely, mek1 disruption is embryonic lethal in the
recessive condition (121, 122). Homozygous mek1 mutants die between embryonic day
(E) 8.5 (121) and E10.5 (122) as a result of placental defects.
MEK1 can downregulate MEK2-dependent ERK signaling (121). The MEK
heterodimer is negatively regulated by ERK-mediated phosphorylation of MEK1 on
Thr292, a residue that is absent in MEK2 (121, 123, 124). If MEK1 is absent or unable to
bind MEK2, the negative feedback phosphorylation loop in which ERK inhibits MEK1 is
lost and MEK2-dependent phosphorylation and activation of ERK is prolonged (121).
mek1-/- fibroblasts migrate more slowly than wild-type counterparts in response to
fibronectin (122). However, mek1 ablation enhances growth factor-induced fibroblast
migration due to increased ERK activation in MEK1-deficient cells (121).
MEK1/2 catalyze the phosphorylation of ERK1/2 on Thr202/185 and
Tyr204/187(125). Phosphorylation at both sites is necessary for significant kinase
activity, with phosphorylation at the tyrosine preceding that at the threonine (126).
ERK1/2 catalyze the phosphorylation of serine/threonine residues that occur in the
sequence Ser/Thr-Pro (127), also known as proline-directed phosphorylation. Known
substrates of ERK1/2 include the nuclear targets, TCF (ternary complex factor) family of
transcription factors and MSK (mitogen- and stress-activated protein kinases), and the
cytoplasmic target, p90 ribosomal S6 kinase (RSK) (128). ERK1 and ERK2 are 84%
identical in sequence and share many, if not all, functions (129). However, the erk1 gene
is dispensable for normal development of mice, but ablation of erk2 is embryonic lethal
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(130-132) suggesting that differences in function (at least during development) are
present.
EGFR is a potent activator of ERK1/2, but a weak activator of the PI3K pathway
(133). However, at low levels of EGF stimulation, PI3K activity induces recruitment of
Grb2-associated binding partner (GAB) to the membrane and contributes to ERK1/2
pathway activation. With prolonged EGF stimulation, the dependency on PI3K is
decreased as EGFR recruits Shc-Grb2-SOS1/2 complexes that activate the Ras/ERKdependent signaling (134). Long-lasting pulses of EGF-induced ERK1/2 activity can
persist over the course of 4-5 consecutive cell divisions (135).

Scaffold proteins
Scaffold (or adaptor) proteins are used by the cell to confer spatial or temporal
regulation of cellular signaling (136). There are several scaffolding proteins that interact
with members of the RAF/MEK/ERK signaling cascade, and they are predicted to restrict
ERK to certain subcellular compartments (137). For example, Kinase suppressor of Ras
1 and 2 (KSR1/KSR2) interact with B-RAF, C-RAF, MEK1/2, and ERK1/2 and scaffold
Ras-dependent signaling effectors at the plasma membrane (see below) (138). IQGAP1
is a large, widely expressed protein that modulates actin dynamics, microtubule
dynamics, cell-cell adhesion, and transcriptional regulation (139). IQGAP1 binds to BRAF, MEK1, MEK2, ERK1, and ERK2 regulating their activation in response to EGF
(140-142) and CD44 (143). While ERK is constitutively bound to IQGAP1 and binding is
not sensitive to EGF stimulation, the interaction between IQGAP and MEK1 increases
and the IQGAP1/MEK2 interaction decreases following EGF treatment (141). Knockout
of IQGAP renders B-RAF insensitive to EGF stimulation (142).
β-arrestins desensitize and promote the internalization of G protein-coupled
receptors (GPCRs) (139). Following activation, GPCRs are phosphorylated and
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internalized to terminate signaling. β-arrestins recruit RAF, MEK1/2, and ERK1/2 to the
GPCRs enhancing the activation of ERK, and accompany the receptors to early
endosomes (139). β-arrestins prevent the translocation of active ERK1/2 to the nucleus,
restricting ERK to cytosolic substrates. Therefore, β-arrestins spatiotemporally regulate
GPCR-induced ERK1/2 activation (139, 144, 145).
MEK partner 1 (MP1) binds only the MEK and ERK interaction and tethers MEK
and ERK at the endosomes, which is critical for full ERK activation (146, 147). Several
scaffolds have been characterized that specifically bind to and enhance the activation of
MEK1, but not MEK2 (141, 148-150). For example, MP1 and its binding partner p14,
specifically organize MEK1 and ERK1 to coordinate signaling through early and/or late
endosomes (139, 146, 149).
Sef (Similar expression to FGF) is a transmembrane scaffold for MEK1/2 and
ERK1/2 that anchors these effectors to the Golgi apparatus. Sef only binds to activated
MEK1/2 and inhibits the dissociation of the MEK-ERK complex, preventing ERK1/2
translocation to the nucleus and promoting the ERK-dependent phosphorylation of
specific cytoplasmic substrates (151).

KSR1
Deletion or loss-of-function alleles of ksr1 suppress the rough eye and multivulval
phenotypes of activated Ras in Drosophila melanogaster and Caenorhabditis elegans,
respectively (152-154). KSR proteins constitute a novel family of proteins that have
remarkable overall structural similarity to proteins of the RAF family (138). All members
are characterized by the presence of five conserved regions (CA1-5) (152) (Fig 1.3). The
CA1 is a 40 amino acid region unique to KSR proteins, and its function remains
undefined. The CA2 is a proline-rich region, the CA3 is a cysteine-rich, zinc-finger
domain, the CA4 is a serine/threonine-rich region, and the CA5 is a putative kinase
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domain (138, 152, 155). Further dissection of the KSR protein suggests that the positive
effects on ERK signaling are mediated by amino acids 319-390 which correspond to the
CA3 (156, 157), while the inhibitory effects appear to be mediated by the kinase-like
domain (CA5) (158, 159). KSR and RAF both have kinase domains in the C-terminal half
of the protein. However, the kinase-like domains of human and mouse KSR1 lack a
critical lysine in the ATP-binding domain, which is responsible for hydrolysis and transfer
of the γ-phosphate group of ATP, and is conserved in other kinases (160). The lack of
conservation at this amino acid renders the kinase inactive. Furthermore, KSR1 does not
contain conserved residues that correlate with peptidic recognition sequences that are
found in both serine/threonine and tyrosine kinases (138, 154).
KSR1 lacks the RBD that is present in RAF family proteins suggesting that KSR1
does not bind Ras directly. However, KSR1 regulates Ras-mediated signaling because it
functions as a molecular scaffold of the RAF/MEK/ERK kinase cascade that enhances
oncogenic signaling. Both MEK1 and MEK2 bind directly to the CA5 region of KSR (157,
158). MEK is stably associated with KSR in both quiescent and growth factor-stimulated
cells (161, 162). However, their dissociation may be necessary for maximal cellular
transformation, as cells harboring KSR1 mutations that disrupt KSR1-MEK interactions
(KSR1C809Y) have increased colony formation in soft agar (unpublished observations,
Kortum & Lewis). ERK1/2 binding is induced upon Ras activation at the FxFP motif in
the CA4 domain of KSR (161, 163, 164). The KSR1 interaction with RAF is also Rasdependent, but requires interactions with other proteins, such as MEK (155, 165).
KSR1 regulates the intensity and duration of ERK activation to modulate cellular
proliferation and oncogenic potential (166). The intensity and duration of ERK activation
are critical to the regulation of downstream processes (167-170). For example, in PC12
cells, EGF induces a transient activation of ERK leading to proliferation, while stimulation
with nerve growth factor (NGF) leads to prolonged ERK activation and translocation to
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Fig 1.3 Conserved domains of KSR proteins.
Murine KSR1 (873 AA) and KSR2 (947 AA) are depicted above. All KSR proteins share
five conserved areas (CAs). CA1 is a 40-residue domain unique in KSR proteins and is
necessary for KSR/RAF complexes. CA2 is a proline-rich stretch. CA3 is a cysteine-rich,
zinc-finger domain that promotes translocation to the plasma membrane.
Phosphorylation of serine residues (S*) on each side of CA3 is required of 14-3-3
binding and sequestration in the cytoplasm. CA4 is a serine/threonine-rich region that is
highly phosphorylated and required for ERK binding. CA5 is a kinase-like domain that
lacks kinase catalytic function, but is necessary for KSR/MEK interactions.
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the nucleus to promote differentiation (168). In MEFs, treatment with EGF again leads to
transient ERK activation, whereas prolonged activation with PDGF induces
phosphorylation of immediate early proteins and cell cycle progression (167, 170). Loss
of KSR1 reduces growth factor-induced ERK activation in MEFs (166). Furthermore,
KSR1 is necessary and sufficient for RasV12-driven transformation in MEFs, with an
optimal dosing level similar to that observed with maximal ERK signaling. Cells
expressing increasing levels of KSR1 have increased EGF- and PDGF-induced ERK
activation. However, after reaching a maximal level of ERK activation, higher levels of
KSR1 actually reduce ERK signaling to levels at or below controls (166). The
mechanism by which excessive levels of KSR1 repress ERK signaling is undefined. It is
predicted that when KSR1 is overexpressed it forms separate complexes with RAF,
MEK, and ERK preventing the complex composition needed for maximal ERK signaling.
KSR1 also interacts with caveolin-1 and is responsible for MEK/ERK
redistribution to the caveolin-1-rich fractions of the plasma membrane (171). The
interaction between KSR1 and caveolin-1 is necessary for optimal ERK activation, as
cells containing a KSR1 mutant unable to bind caveolin-1 are deficient in the early
stages of growth factor-mediated ERK activation (171). Moreover, KSR1 modulates
RasV12-induced replicative senescence in MEFs (172). Oncogenic Ras induces cell
growth arrest by RAF/MEK/ERK-mediated activation of p19ARF/p53 and INK4/Rb tumor
suppressor pathways. H-RasV12 fails to induce p53, p19ARF, p16INK4a, and p15INK4b
expression in MEFs lacking KSR1 resulting in proliferation instead of growth arrest
(172). Abolishing the interaction between KSR1 and caveolin-1 also has adverse effects
on H-RasV12-induced senescence and transformation (171). Taken together, these data
demonstrate that KSR1 is a potent modulator of Ras signaling.
KSR1 is phosphorylated on multiple residues that may be involved in the
subcellular distribution of KSR1 resulting in significant effects on ERK signaling (173,
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174). Members of the MARK family, C-TAK1 and EMK, and nm23H1 all phosphorylate
KSR1 at Ser392 (175-177). C-TAK1-mediated phosphorylation of KSR1 on Ser297 and
Ser392 is crucial for KSR1 to interact with the regulatory protein 14-3-3 (163, 176). In
unstimulated cells, the 14-3-3 binding of KSR1 sequesters it in the cytoplasm. Growth
factor stimulation and Ras activation, induces protein phosphatase 2A (PP2A)dependent dephosphorylation of KSR1 on Ser392 releasing 14-3-3 and exposing the
CA3 region, which is essential for translocation and accumulation at the plasma
membrane (178). KSR1 is rapidly translocated to the plasma membrane, where it can
promote the Ras/MAPK pathway activity (176, 178).
KSR1 phosphorylation at both Thr274 and Ser392 modulates the proliferative
potential of EGF- and PDGF-dependent signaling (179). Expression of KSR1 mutated at
Thr274 and Ser392 promotes sustained ERK1/2 activation in response to treatment with
either EGF or PDGF and accelerates cell cycle progression (179). Normally, the EGF
response is transient and does not promote S-phase entry. However, blocking KSR1
phosphorylation at these sites induces a PDGF-like response to EGF stimulation. It is
predicted that phosphorylation at these two sites promotes the degradation of KSR1, as
the mutant has an increased half-life, which results in increased proliferation and colony
formation in soft agar (179).
Four sites on KSR1 (Thr260, Thr274, Ser320 and Ser443) are phosphorylated
upon growth factor stimulation or expression of H-RasV12 (163, 180). Mutations at these
sites had no effect on Ras-dependent signaling or the ability of KSR1 to scaffold the
RAF/MEK/ERK pathway (163), but docking of ERK1/2 on KSR1 accelerated the
phosphorylation (181). Phosphorylation of KSR1 (and BRAF) by ERK1/2 promotes the
dissociation of BRAF/KSR1 complexes and promotes the release of KSR1 from the
membrane (181). This negative feedback loop can thereby modulate the duration of
KSR1-dependent signaling.
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The Ras effector protein IMP (impedes mitogenic signal propagation) modulates
Ras-dependent signaling by inactivating KSR1 (182, 183). IMP promotes KSR1
hyperphosphorylation and localizes KSR1 to a detergent-insoluble fraction (183). IMP
overexpression inhibits H-Ras- and C-RAF-mediated transformation in cells by
preventing MEK1/2 activation by C-RAF. Upon H-RasV12 expression or growth factor
stimulation, IMP is autopolyubiquitinated and degraded, releasing KSR1 to translocate to
the plasma membrane (183). Overall, these data demonstrate that KSR function is
regulated via phosphorylation and compartmentalization through complex formation.
ksr1-/- mice are grossly normal despite suppressed ERK activation. However,
they are resistant to murine polyoma middleT-driven tumor formation (184). Additionally,
mice lacking ksr1 have disorganized hair follicles (185) and have fewer and enlarged
adipocytes as compared to their wild-type counterparts (186). In vitro, deletion of ksr1
prevents the ERK- and RSK-dependent phosphorylation and stable expression of the
transcription factor C/EBPβ, which is required for the subsequent expression of C/EBPα
and PPARγ necessary for adipogenesis. Interestingly, increasing KSR1 expression to
levels that promote maximum ERK activation actually inhibits the adipogenic program by
promoting the phosphorylation of PPARγ at an inhibitory site (186). These data suggest
that controlled expression of KSR1 ensures appropriate levels of ERK activity for
progression through the adipogenesis program.
In MEFs, KSR1 enhances the glycolytic and oxidative phosphorylation potential
of cells by inducing the expression of the metabolic regulators peroxisome proliferatoractivated receptor gamma coactivator 1α (PGC1α) and estrogen-related receptor α
(ERRα) only in the presence of activated Ras (187). This pathway is essential for the
transformation of cells by oncogenic Ras. In ksr1-/- MEFs expressing H-RasV12, ectopic
PGC1α is sufficient to rescue ERRα expression, metabolic capacity, and anchorageindependent growth. The ability of PGC1α to promote anchorage-independent growth
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requires its interaction with ERRα. Conversely, the expression of a constitutively active
ERRα in ksr1-/- cells with H-RasV12 is sufficient to normalize the metabolic capacity, but
not rescue anchorage-independent growth (187).
PGC1α was not detected in colon tumor cell lines. However, a related gene
PGC1β and the same coactivator, ERRα, were identified as downstream effectors of
Ras signaling in CRC cells and tumors (188). KSR1 is overexpressed in colon tumor
cells as compared to expression in immortalized, but not transformed human colonic
epithelial cells (HCECs) (188). HCECs were isolated from normal human colon and
immortalized with CDK4 and human telomerase reverse transcriptase (hTERT). HCECs
maintain wild-type adenomatous polyposis coli (APC), K-Ras, and TP53 proteins. They
also form crypt-like structures in 3D culture, but are incapable of anchorage-independent
growth or tumor formation in nude mice (189). Depletion of KSR1 is selectively toxic to
the cancer cells and is required for anchorage-independent growth and tumor
maintenance in colon cancer cell lines (188). The downstream effectors of KSR1dependent signaling, PGC1β and ERRα, are also upregulated in colon tumor cells.
Suppression of PGC1β or ERRα expression decreases tumor colon cell viability and
anchorage-independent growth, as well as delays and suppresses tumor formation in
nude mice (188). Taken together, these data suggest that targeting KSR1 or its
downstream effectors may be a successful approach to target colon cancer.

Targeting Ras signaling
Targeting Ras and other components of Ras-dependent signaling has been
extensively explored and is an ongoing area of investigation. Here we summarize the
different levels of Ras signaling that have been targeted clinically and present preclinical work on innovative ways being developed to target Ras directly.
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For patients harboring tumors with high EGFR expression and wild-type K-ras,
treatment with monoclonal antibodies against EGFR, such as cetuximab and
panitumumab, has significant clinical benefit (190-193), whereas negligible responses
are observed with patients carrying mutant K-ras (192, 194). Overall, tumor-free
progression and overall survival is better in patients with wild-type K-ras (195). In
colorectal cancer, resistance to EGFR inhibitors seems to develop through selection of
preexisting clones that contain K-ras mutations (196).
The post-translational modifications of Ras have been prime targets of Ras
inhibition. Farnesyltransferase inhibitors (FTIs) were developed to simulate the CAAX
motif of Ras and were used as competitive inhibitors to block the post-translational
processing needed for Ras activation. Mouse studies showed regression of MMTV-Hras-driven mammary carcinomas with FTI treatment with no detectable systemic
toxicities (197). However, unlike H-Ras, N-Ras and K-Ras are subsequently modified
with an alternative prenylation catalyzed by geranylgeranyltransferase 1 (GGTase-1)
making them insensitive to FTIs (198, 199).
Targeted inhibition of RCE1 and ICMT1 in NIH-3T3 cells and yeast (ste14)
indicated that blocking proteolytic cleavage of Ras was not sufficient to inhibit its
functions (200, 201). More recently, it was shown that rce1-deficient mice have a 50%
reduction in membrane-bound K-Ras and H-Ras corresponding with decreased tumor
xenograft growth of mouse skin carcinoma cells (202). Similar studies targeting ICMT1 in
MEFs show partial reduction in membrane association of K-Ras with concomitant loss of
tumorigenesis (203). Compounds targeting ICMT1, such as methotrexate, have some
effectiveness in MEFs and DKOB8 human CRC cells in cell culture and animal models
(204, 205).
While direct targeting of Ras has been difficult, studies have shown that a
reduction in K-Ras expression in cancerous cells, by antisense, miRNA or siRNA
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oligonucelotides, halts proliferation and leads to cellular death (206, 207). A new
approach involves targeting DNA secondary structures called G-quadruplexes in the
promoter of K-ras (208). Instead of forming the traditional double-helix, negative
superhelicity induced by transcription can promote local unwinding of the DNA in these
G/C-rich regions allowing for rearrangement of the guanine-rich strand to form planar
structures via hydrogen bonds between four guanine residues known as Gquadruplexes. Formation of G-quadruplexes in DNA has been shown to modulate
transcription and in RNA modulates translation. Strategies to stabilize the Gquadruplexes in the K-ras promoter, thereby reducing its transcription, are currently
underway (208).
Other strategies for targeting Ras focus on inhibition of the downstream signaling
pathways. B-RAF-specific, ATP-competitive inhibitors (such as vemurafenib) have
shown promise in the clinic in melanoma patients with mutant B-RAF (B-RAFV600E) (209).
However, there is a paradoxical effect in that they accelerate the growth of cells with
mutant Ras (210-212). Paradoxical activation is caused by transactivation resulting from
the induction of RAF homo- (C-RAF/C-RAF) and heterodimers (B-RAF/C-RAF) (112). In
the presence of RAF inhibitors and activated Ras, the drug binds directly to the ATPbinding site of one kinase (the “activator” kinase) and promotes the transactivation of the
other kinase in the dimer (the “receiver” kinase) (112, 116). In B-RAFV600E tumors, K-Ras
is not activated, as these mutations are mutually exclusive (213). Thus, transactivation is
minimal and ERK signaling is inhibited (112). Additionally, RAF inhibition in the absence
of activated Ras induces the dimerization of B-RAF and KSR1 to inhibit downstream
ERK activation (181). This is likely due to the fact that KSR1 is not a kinase and B-RAF
is bound to the inhibitor; thus, there is no “receiver” kinase to transactivate.
RAF inhibitor PLX4720 does not induce B-RAF/C-RAF dimers, but still activates
MEK and ERK in transformed cells (112, 210, 214). B-RAF inhibitors PLX4720 and
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GDC0879 induce the dimerization of C-RAF and KSR1. While KSR1/B-RAF complexes
inhibit ERK signaling (181), KSR1/C-RAF dimerization promotes ERK signaling. These
inhibitors also require KSR1 to activate MEK and ERK in Ras-transformed cells (113).
RAF transactivation requires phosphorylation of an N-terminal acidic domain in the
“activator,” but not the “receiver” kinase. This motif is located between residues 446-449
and is constitutively phosphorylated in B-RAF, but not in C-RAF and KSR1 (116).
However, point mutations in equivalent regions of KSR1 and C-RAF (KSR1YLQE/DDEE and
C-RAFSSYY/DDEE) in kinase-dead constructs (KSR1A587F or C-RAFA373F) resulted in potent
ERK activation (116). Together, these data solidify the idea that RAF kinases (and
KSR1) form functionally asymmetric dimers, and that this is a mechanism of resistance
to RAF inhibitors in the presence of activated Ras.
Direct inhibition of MEK has not been clinically successful in achieving increasing
progression-free survival. Preclinical studies identified distinct mechanisms by which
cells acquire resistance to MEK inhibition, including amplification of B-RAF (215), STAT3
upregulation (216), or acquisition of mutations in the binding pocket of MEK that block
inhibitor binding (217, 218). MEK inhibition also induces paradoxical activation of the
ERK pathway. This is due to loss of negative feedback loops. Activated ERK can directly
phosphorylate both RAF (219) and MEK1 (123, 124) suppressing RAF/MEK/ERKdependent signaling. In the absence of ERK-dependent MEK inhibition, MEK can
continue to activate ERK. This mechanism also operates in K-Ras-mutated colorectal
cancer cells and induces AKT activation in response to MEK inhibition (220).
Inhibition of ERK overcomes acquired resistance to MEK inhibition (221). Several
compounds have been developed that target ERK1/2 directly (221-224). FR18024 is an
ATP-competitive inhibitor that has not been completely characterized (225). VTX-11e is
a potent ATP-competitive ERK inhibitor with oral bioavailability (223). SCH772984 is a
recently identified, highly potent and selective inhibitor of ERK1/2 (224) that induces a
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novel allosteric pocket adjacent to the ATP binding site contributing to high selectivity
and low off-rate (226). Direct ERK inhibition is a relatively new way to target Ras
signaling. Further preclinical testing needs to be completed before its clinical viability can
be assessed.

Summary
It has been more than 30 years since the first gene associated with rat sarcoma
virus was identified in human tumors (227). Since then, we have learned an enormous
amount regarding structure, activation, and downstream signaling pathways, only some
of which is summarized here. However, targeting Ras signaling in cancers remains a
moving target. Each therapy has resulted in the discovery of acquired or even innate
tumor resistance. This has been beneficial in further mapping of the extensive network of
Ras-dependent signaling, including both positive and negative feedback loops, but is
increasingly frustrating for the future of clinically relevant therapeutics targeting Ras.
Here we identify new ways to target Ras-dependent signaling in colon cancer
cells and further define Ras/RAF/MEK signaling networks. The studies described in this
dissertation examine the following topics:
1)

Identification of KSR1 and EPHB4 as vulnerabilities in colon cancer
that regulate Myc and PGC1β expression

2)

Characterization of MEK-dependent signaling, including the ERK- and
HSF1-dependent regulation of Myc and PGC1β expression
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Gene expression-based high-throughput screen and functional
signature ontology analysis
The gene expression-based high-throughput screen has been previously described
(188, 228). The gene expression-based signature measured in the screen is based on
six genes (ACSL5, BNIP3L, ALDOC, LOXL2, BNIP3, and NDRG1) that are consistently
affected by KSR1 depletion as well as two housekeeping genes (PPIB and HPRT) that
were included for normalization. To identify targets that are KSR1 functional analogs
based on their gene expression-based signature, two similarity metrics were employed,
Euclidean distance (ED) and Pearson correlation (PC). KSR1-depleted positive controls
cluster with a low ED and high PC. Linear regression analysis was used to establish a
cutoff (PC > 0.25 * ED + 0.5) for KSR1 similarity based on the ED and PC values of
KSR1 positive controls. Targets that clustered with the positive control KSR1-depleted
wells and exceeded the established cutoff based on these two metrics were designated
as possible KSR1 functional analogs and candidates for further evaluation.

Cell culture
Colorectal cancer cell lines HCT116, SW480, DLD1, SK-CO-1, Caco2, and HCT15 were
purchased from American Type Culture Collection (ATCC). The CBS and GEO
colorectal cancer cell lines were gifts from Dr. Michael Brattain (U. Nebraska Med. Ctr.).
Cells were grown in either Dulbecco’s modified Eagle medium (DMEM) or Eagle’s
minimum essential medium with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and
0.1 mM nonessential amino acids (NEAA). All colorectal cancer cells were grown at
37°C with ambient O2 and 5% CO2. Immortalized non-transformed human colonic
epithelial cell lines (HCEC) were a gift from J. Shay (UT Southwestern) (189). HCECs
were grown in medium composed of 4 parts DMEM to 1 part medium 199 (SigmaAldrich) with 2% cosmic calf serum (GE Healthcare), 25 ng/mL EGF, 1 µg/mL
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hydrocortisone, 10 µg/mL insulin, 2 µg/mL transferrin, 5 nM sodium selenite, and 50
µg/mL gentamycin sulfate. HCECs were grown in a hypoxia chamber with 2% O2 and
5% CO2 at 37°C.

siRNA transfections
Pooled or individual (Table 2.1) siRNAs targeting EPHB4 (M-003124-02), KSR1 (LU003570-00-0002), Myc (L-003282), MAP2K1 (J-003571), MAP2K2 (J-003573), MAPK3
(J-003592), MAPK1 (J-003555), HSF1 (M012109), as well as a non-targeting siRNA
control (D-001810-01) (DharmaconGE), were introduced into HCT116 or Caco2 cells
using the Lipofectamine RNAiMAX (Invitrogen) reverse transfection protocol per
manufacturer’s instructions. Briefly, 125 pmol of siRNA and 5-7 µL of RNAiMax were
combined in OPTI-MEM for 5 minutes. DNA:Lipofectamine complexes were overlaid with
2 mL of cells (150,000 cells/mL) in 6-well plates. Final RNAi concentrations are 50 nM.
HCECs were transfected following the RNAiMax reverse transfection protocol using 2.5
µL RNAiMax transfection reagent per 6 mL of antibiotic free-medium and 150,000
cells/mL with a final RNAi concentration of 10 nM in 6-cm dishes (CorningTM,
PrimariaTM). After a 72-hour transfection, cells were lysed in RIPA lysis buffer with
protease and phosphatase inhibitors (described below).

Reagents
The EPHB4 receptor tyrosine kinase inhibitor (AZ12672857) was a gift from J. Kettle
(AstraZeneca). The EPHB4 inhibitor was dissolved in DMSO to achieve a stock
concentration of 10 mM. Z-Leu-Leu-Leu-al (MG132, C2211), cycloheximide (CHX,
C7698), Bafilomycin A1 (BafA1, B1793), poly-2-hydroxyethyl methacrylate (polyHEMA,
P3932), and propidium iodide (PI, P4170) were purchased from Sigma-Aldrich and were
used at the concentrations specified in the figures and accompanying text.
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Table 2.1 Sequences of individual siRNA duplexes
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Anchorage-independent growth on poly-2-hydroxyethyl methacrylate
(polyHEMA)-coated plates
polyHEMA stock solution (10 mg/mL) was made by dissolving polyHEMA in 95% ethanol
and shaking at 37°C until fully dissolved (6 hours to overnight). Black-sided, clearbottom, 96-well plates were coated with polyHEMA by evaporating 200 µl of the 10
mg/mL stock polyHEMA solution in each well. Cells were plated in complete medium on
polyHEMA-coated wells at a concentration of 2 x 104 cells/100 µl 48 hours posttransfection (as described above). Cell viability was measured per the manufacturer’s
protocol using the CellTiter-Glo® Luminescent Cell Viability Assay (Promega).
Specifically, this was done by adding 90 µl of CellTiter-Glo® reagent, shaking for two
minutes to lyse the cells, incubating at room temperature for 10 minutes, and measuring
luminescence (POLARstar OPTIMA).

Cell growth assay
Cells (5,000/well) were transfected on white, 96-well plates. Transfections were done as
described above but at a ratio of 1:25 for all of the reagents. At 0 and 72 hours posttransfection, 10 µL of alamarBlue® (ThermoFisher Scientific) was robotically added to
each well. Plates were incubated at 37°C for three hours and fluorescence was
measured (POLARstar OPTIMA).

Propidium iodide staining
Cells were assayed for apoptosis using the sub-G1 peak measured following propidium
iodide (PI) staining. Prior to staining, all medium in each sample well was collected and
placed in a 12 x 75 mm round bottom polystyrene tube (BD Falcon, 352054). Cells were
washed once with PBS, the PBS was saved, and cells were subsequently treated with
0.25% trypsin for 5-10 minutes. Saved medium was then used to resuspend the trypsin-
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treated cells from the corresponding wells, which were collected and placed in the
polystyrene tubes. Cells were pelleted by centrifugation for 5 minutes at 2800 RPM
using an Immunofuge II. The supernatant was aspirated, and the cell pellets were
resuspended in 2 mL of PBS, then pelleted again by centrifugation for 3 minutes at 2800
RPM. The PBS was aspirated and the cells were fixed in 2 mL of ice cold 70% ethanol
for at least one hour at -20°C. Cells were then warmed to room temperature (~15
minutes), pelleted by centrifugation for 3 minutes, then rehydrated in 2 mL of room
temperature PBS and incubated at 37°C for 15 minutes. Cells were then pelleted, the
PBS aspirated, and the cells were resuspended in PI stain overnight. Data was acquired
using a Becton-Dickinson FACSCalibur flow cytometer and analyzed using ModFit
analysis software to detect a sub-G1 peak of fluorescence.

Western blot analysis
Whole-cell lysate extracts were prepared in radioimmunoprecipitation assay (RIPA)
buffer composed of 50 mM Tris-HCl, 1% NP-40, 0.5% Sodium deoxycholate, 0.1%
Sodium dodecyl sulfate, 150 mM NaCl, 2mM EDTA, 50 mM NaF, 10 µg/mL aprotinin, 10
µg/mL leupeptin, 2 mM EDTA, 1 mM PMSF. Cytoplasmic and nuclear fractionations
were performed using NE-PER Nuclear/Cytoplasmic Extraction Reagents (Thermo
Scientific, 78835) Protein concentration was determined using the Promega BCA protein
assay. Samples were diluted in 1X sample buffer (5X stock – 313 mM Tris-HCl pH 6.8,
10% SDS, 50% glycerol, 0.05% bromophenol blue) with 100 mM DTT (20X stock = 2 M).
SDS-PAGE was performed, membranes were blocked in Odyssey PBS blocking buffer
(LI-COR Biosciences, 927-40000), and incubated in primary antibody (listed below)
overnight at 4°C. LI-COR secondary antibodies (IRDye 800CW, 680LT, or 680RD) were
diluted 1:5000-1:10,000 in 0.1% TBS-Tween 20 (for nitrocellulose) or 0.1% TBST +
0.01% SDS (for PVDF). Membranes were imaged using the LI-COR Odyssey.
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Antibodies
Primary antibodies were diluted as follows: EPHB4 (mAb 265, a gift from
Vasgene) 1:500 and (D1C7N, 14960, Cell Signaling) 1:1000; KSR1 (H-70, Santa Cruz)
1:1000; α-tubulin (B-5-1-2, Santa Cruz) 1:2500; β-actin (C-4, Santa Cruz) 1:2000;
PGC1β (provided by Dr. A. Kralli, The Scripps Research Institute) 1:5000; c-Myc (5605,
Cell Signaling) 1:1000; PARP (9542, Cell Signaling) 1:1000; pERK (9106, Cell Signaling)
1:1000; ERK (9102, Cell Signaling) 1:1000; pMEK (4694, Cell Signaling) 1:1000; MEK
(9122, Cell Signaling) 1:1000; pMyc T58 (ab85380, Abcam) 1:500, pMyc S62 (ab78318,
Abcam) 1:500; FBW7 (CDC4 H-300, Santa Cruz) 1:1000; β-TrCP (4394, Cell Signaling)
1:1000; and HDAC2 (ab7029, Abcam) 1:5000; PDCD4 (D29C6, 9535, Cell Signaling)
1:1000); p4E-BP1 T70 (9455, Cell Signaling) 1:1000; eIF4A (C32B4, 2013, Cell
Signaling) 1:1000; eIF4E (9742, Cell Signaling) 1:1000, peIF4E S209 (9741, Cell
Signaling) 1:1000; 4E-BP1 (53H11, 9644, Cell Signaling) 1:1000.

RT-qPCR
RNA was harvested using 1 mL TriReagent (MRC, TR118) and stored at -80°C until
extraction. RNA was extracted per manufacturer’s protocol and final RNA pellets were
resuspended in nuclease-free water. DNase digestion was performed (Qiagen, 79254)
and RNA cleanup was completed (Qiagen, 74106). RNA was quantified using the
NanoDrop 2000 (Thermo Scientific). Reverse transcription was performed using
iScript™ Reverse Transcription Supermix for RT-qPCR (Bio-Rad, 170-8840) with 1 µg of
total RNA per 20 µL reaction. RT-qPCR was performed using the primers and conditions
listed in Table 2.2. All targets were amplified using SsoAdvanced™ Universal SYBR
Green Supermix (Bio-Rad) with 40 cycles of a 2-step program (95°C x 5 sec, Tm x 45
sec) on an MX3000P (Stratagene). Data were normalized using two of the normalization
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Table 2.2. Sequences of qPCR primers
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genes listed here: HPRT, β-actin, and/or GAPDH. Analysis was performed according to
the q-base protocol, as previously published (229).

TCGA
mRNA expression was analyzed based on the RSEM normalized RNA-Seq values of
primary tumor (n=285) and normal solid tissue (n=41) samples as well as patientmatched samples (n=26) within The Cancer Genome Atlas (TCGA) Colon
Adenocarcinoma (COAD) dataset. Results were analyzed for statistical significance
using unpaired and paired Student’s t tests for the unpaired and patient-matched
samples, respectively.

Myc translation
Myc translation reporter constructs (pGML, phpL and phpmL) for luciferase assays were
a gift from Anne Willis (Medical Research Council, Leicester, UK) (230, 231). RNAi
depletions were performed in 6-well plates as described above. The following day, cells
were transfected with 3 µg of the translation vector and 1 µg of pSV-β-galactosidase
vector (Promega, E1081) using 10 µL of Lipofectamine 2000 (Invitrogen) per well. After
24 hours, luciferase and β-gal expression was assessed using Dual-Light® System
(Applied Biosciences, T1003) according to the manufacturer’s instructions. Briefly, cells
were rinsed twice with PBS, lysed with Lysis Solution (100 mM potassium phosphate pH
7.8, 0.2% Triton X-100, 0.5 mM DTT), and 10 µL of each lysate was added (in triplicate)
to a 96-well plate. Luminescence was measured (POLARstar OPTIMA) for 1 second per
well. When quantifying basal translation from each vector, luciferase expression was
normalized to β-galactosidase expression. When comparing the affect of KSR1 or
EPHB4 depletion on Myc translation, luciferase signal was normalized to protein input.
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Statistical analysis
P and EC50 values were calculated using Prism Software (GraphPad, La Jolla, CA). A P
value of less than 0.05 was considered statistically significant. Values presented here
are shown as mean +/- standard deviation (SD) unless otherwise noted. EC50 values
were calculated in Prism using an algorithm for fitting non-linear curves with variable
slopes.
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Chapter 3: KSR1 and EPHB4 regulate Myc and PGC1β to
promote survival of human colon tumor cells

Portions of the material covered in this chapter are the topic of a manuscript
submitted for publication by McCall JL, Gehring D et al.
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Introduction
Colorectal cancer (CRC) is the third most common cancer in the U.S. and
worldwide (232). It is sporadic in nature with only 15-30% having a major hereditary
component (233, 234). CRC is a heterogeneous disease with distinct molecular features
of the tumor contributing to the prognosis and response to targeted therapies (235).
Several critical genes and pathways are important in the initiation and progression of
CRC, most notably the Wnt, Ras/MAPK, PI3K, TGFβ, p53, and DNA mismatch-repair
pathways (236). Oncogenic Ras mutations commonly occur in human CRC, with
approximately 43% of patients harboring activating K-Ras mutations (237). Patients
carrying an oncogenic form of Ras have poorer prognoses compared to patients
harboring wild-type Ras (238-240). Their poor response to therapy can be attributed to
the observed attenuation in benefit from anti-epidermal growth factor receptor (EGFR)
therapies (241) or resistance to RAF inhibitor therapies (242). Ras proteins are a family
of small GTPases that regulate a number of cellular signaling pathways associated with
the promotion of an oncogenic phenotype, particularly through the MAPK and PI3K
pathways (243). The MAPK signaling pathway is composed of the downstream signaling
molecules RAF, MEK, and ERK, whose subcellular locations are modulated by KSR1
(244). KSR1 is a scaffold of the RAF/MEK/ERK kinase cascade and is required for
maximal MAPK-dependent signaling (180, 245). While KSR1 is required for the survival
of CRC cells, it is dispensable in normal colon epithelial cells (188). ksr1-/- mice develop
normally with attenuated ERK signaling and display a reduced tumor burden in an
MMTV-driven mouse tumor model (185, 246). Given that KSR1 is dispensable for
normal cells, but indispensable for colorectal cancer cells, we sought to detect and
exploit further vulnerabilities in human colon tumor cells. To do this, we developed a
gene expression-based high-throughput screen and used functional signature ontology
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(FUSION) (188, 228) to identify functional analogs of KSR1. From this screen, we
identified EPH (erythropoietin-producing hepatocellular carcinoma) receptor B4 (EPHB4)
as a KSR1-like, cancer-specific vulnerability that may be exploited by targeted therapies.
EPH receptors are the largest family of receptor tyrosine kinases (RTKs) with
important roles in tissue organization and growth during development as well as in tissue
homeostasis in adults (247-249). Humans have nine EPHA and five EPHB receptors
that are classified by their ability to bind their respective ligands, ephrin (EPH-receptor
interacting protein) A and ephrin B on an adjacent cell. There are five type-A and three
type-B ephrin ligands. Ephrin B ligands are transmembrane and receptor-ligand binding
is capable of transmitting both forward (through the RTK) and reverse (via the ligand)
signaling [reviewed in (250, 251)]. This bidirectional signaling results in repulsion
between the two cells and is responsible for establishing boundaries between distinct
cell types (252, 253). For example, EPHB4 binding to its ligand ephrin B2 contributes to
the establishment of capillaries in the vasculature with EPHB4 expressed primarily in the
venous endothelium and ephrin B2 in the arterial endothelium (254, 255). ephb4 or
ephrin B2 knockout mice are embryonic lethal due to their inability to develop proper
vasculature systems (256-258). In the intestine and colon, EPHB-expressing cells are
present in the progenitor cells of the crypts, whereas the ephrin B ligand is present in the
more differentiated cells (255, 259). The repulsion of EPH-ephrin binding leads to
opposing gradients and contributes to the morphology of the intestine and colonic crypts
(255, 259).
We have recently shown that tumor-specific expression of PGC1β is required for
colon cancer survival (188). Previous work has shown that PGC1β is a direct
downstream target of Myc (260, 261). Myc-dependent PGC1β transcription is inhibited
by hypoxia in renal clear cell carcinoma due to induction of MXI1 (a repressor of Myc
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activity) (261), a mechanism that may be operative in the hypoxic regions of many tumor
types. In breast cancer cells, HER2 and IGF1 signaling regulate PGC1β via induction of
Myc mRNA expression and/or regulation of Myc protein stability. Tight regulation of Myc
expression is essential for normal cell function (262, 263). Dysregulation of Myc occurs
in more than half of all human tumors and often correlates with aggressive disease (264,
265), resistance to therapy (266-268), and poor prognosis (269-271). Myc activates or
represses the transcription of a large number of genes involved in key cellular processes
such as cell proliferation, metabolism, apoptosis, and protein synthesis (272). In cancer
cells, Myc activation can be induced through constitutive activation of a pathway (i.e.,
Wnt activation in tumors with APC mutations) (273), or through alterations of the Myc
gene (i.e., amplification and translocation) (274, 275). Defects in the APC pathway occur
in many human colon carcinomas and result in enhanced TCF-dependent transcriptional
activation of Myc (273). In fact, Myc is essential for the for the “crypt progenitor cell-like”
phenotype of APC-deficient cells in vivo (259). Simultaneous deletion of APC and Myc in
the murine adult small intestine rescued the phenotypes of APC deficiency; cells
proliferated, differentiated, and migrated like wild-type intestinal enterocytes (276).
Additionally, Ras activation and subsequent phosphorylation events enhance
Myc protein stability (277, 278). Constitutive expression may cause Myc to bind to and
activate E-box-driven genes that would be regulated by other E-box transcription factors
in normal nonproliferative cells, thereby increasing the downstream targets of Myc in
cancer cells (279). Recent work from The Cancer Genome Atlas (TCGA) Network
discovered that, in a comprehensive examination of human colon and rectal cancers of
diverse anatomical origin and mutation status, changes in Myc transcriptional targets
were found in nearly all of the tumors (280), suggesting an important role for Myc in
CRC. While a promising target for CRC, Myc is a transcription factor and traditionally
considered “undruggable” (262, 281). Although there are new strategies emerging to
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inhibit Myc, including interrupting key dimerization events or DNA binding (262), finding
additional or alternative ways to target Myc protein expression or its downstream
effectors may provide therapeutic benefits to many cancer patients.
Here we examined EPHB4 and its relationship to Myc and downstream effectors
of KSR1 signaling to identify pathways on which colorectal cancer cells are uniquely
dependent. We show that EPHB4 has phenotypic and molecular effects in colorectal
cancer cells similar to KSR1, and that both KSR1 and EPHB4 are essential for the
survival of colorectal cancer cells, but dispensable for the survival of non-transformed,
immortalized human colonic epithelial cells (HCECs). Additionally, we demonstrate that
both molecules support the expression of PGC1β, which is required for maintaining
tumor cell viability. Finally, we show that EPHB4 supports Myc expression by elevating
Myc mRNA, while KSR1 promotes the expression of PGC1β by enhancing the
translation of Myc mRNA into protein.

Results
EPHB4 is identified as a functional analog of KSR1
Kinase Suppressor of Ras 1 (KSR1) regulates the oncogenic potential of
activated Ras (166). Our lab recently showed that KSR1 also promotes anchorageindependent growth and tumor maintenance in human colon tumor cell lines (188). We
demonstrated that KSR1 is selectively toxic to colorectal cancer (CRC) cells as
compared to immortalized, non-transformed human colonic epithelial cells (HCECs).
Using a gene expression signature representing depletion of KSR1, we developed a
high-throughput screen termed Functional Signature Ontology (FUSION) (228) to
identify functional analogs of KSR1. Details regarding the screen, gene signature, and
FUSION have been described previously (188, 228). Based on unsupervised
hierarchical clustering of reporter gene expression following RNAi-mediated depletions
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of individual genes, we found that knockdown of EPH receptor B4 (EPHB4) clustered
with the RNAi-mediated KSR1 depletion (siKSR1) positive controls. We further
quantified and visualized this relationship by examining and plotting Pearson correlation
versus Euclidean distance similarity metrics (Fig 3.1A, Beth Clymer). Depletion of
EPHB4 has a Euclidean distance of 1.44 and a Pearson correlation of 0.88, and
siEPHB4 (blue) clusters with the siKSR1 (red) reference standards. Based on previous
work demonstrating that gene expression-based signatures can be used to represent the
functional state of a cell (188, 228, 282, 283), the similarity of siKSR1- and siEPHB4dependent gene expression signatures suggests that EPHB4 is likely to share functional
similarity with KSR1.
EPHB4 expression is elevated in a variety of human cancers including cancers of
the head and neck, prostate, bladder, ovaries, large intestine, lung, brain, pancreas, and
the esophagus (269, 271, 284-290). We analyzed the expression of EPHB4 in a panel of
colon tumor cells as compared to its expression in HCECs. Western blotting revealed
that EPHB4 protein is overexpressed in all colon tumor cell lines tested (Fig 3.1B, Drew
Gehring). RT-qPCR analyses demonstrate that the abundance of protein cannot be
entirely attributed to an overabundance of mRNA (Fig 3.1C). While there is a trend
towards increased mRNA levels in all colon tumor cell lines as compared to HCECs,
only SK-CO-1 cells show a statistically significant increase. To evaluate the relevance of
these findings in human tumors, we examined EPHB4 gene expression in the colon
adenocarcinoma dataset within The Cancer Genome Atlas (TCGA) and demonstrated
that EPHB4 is significantly increased at the mRNA level in human colon tumor samples
compared to normal solid tissue samples (Fig 3.1D, Beth Clymer). These findings were
consistent both when using all available data (top) or using only the patient-matched
tumor and normal samples (bottom). In fact, every patient-matched tumor demonstrated
an increase in EPHB4 expression relative to the normal sample.
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Fig 3.1 Genome-scale RNAi screen identifies EPH Receptor B4 (EPHB4) as a
KSR1-like effector.
(A) Identification of EPHB4 as a KSR1 functional analog using Pearson correlation and
Euclidean distance similarity metrics. (B) Western blot and (C) RT-qPCR of EPHB4
levels in a panel of colon tumor cell lines and immortalized, non-transformed HCECs.
RT-qPCR data are shown as mean ± SD. ****p<0.0001 (matched, one-way ANOVA,
Dunnett’s post-test). (D) EPHB4 gene expression (RNA-Seq) data from TCGA for
unpaired primary colon tumors and normal solid tissue samples (top) primary tumors and
patient-matched normal solid tissue samples (bottom). Number (n) of samples analyzed
in each is shown. (A) Student’s unpaired t-test. (B) **** p < 0.0001. Student’s paired ttest. **** p < 0.0001. The results published here are in whole or part based upon data
generated by the TCGA Research Network: http://cancergenome.nih.gov/. (3.1A and
3.1D were performed by Beth Clymer, 3.1B was performed by Drew Gehring)
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Depletion of EPHB4 is selectively toxic to colon tumor cells
Depletion of KSR1 is selectively toxic to colon tumor cells as compared to
HCECs (188). To determine whether EPHB4, like KSR1, is required for tumor cell
survival, we measured viability, anchorage-independent growth, and apoptosis in two
colon tumor cell lines and HCECs following knockdown of KSR1 or EPHB4 by RNAi.
Cell growth was measured by alamarBlue® Cell Viability Assay after 72 hours of KSR1
or EPHB4 depletion. In HCT116 cells, KSR1 and EPHB4 RNAi reduced cell growth as
compared to controls by 81% and 71%, respectively (Fig 3.2), whereas, in the Caco2
cells, cell viability was decreased by 95% with KSR1 depletion and 69% with depletion of
EPHB4. Cell growth was unaffected in the HCEC cell line. To measure anchorageindependent growth, cell growth was measured on a polyHEMA-coated plate (291, 292)
using CellTiter-Glo® Luminescent Cell Viability Assay, as described previously (188).
Following depletion of KSR1 or EPHB4, growth in anchorage-independent conditions
was reduced by 57% and 53% in HCT116 cells and 74% and 51% in Caco2 cells,
respectively (Fig 3.3). HCECs are unable to proliferate in an anchorage-independent
environment and were not used in this experiment. Validation of target knockdown is
shown by western blot in Fig 3.2 and Fig 3.3. To determine if the reduced cell viability in
normal and anchorage-independent conditions is due to increased apoptosis, PARP
cleavage was assessed by western blot following depletion of KSR1 and EPHB4 in
HCECs, HCT116, and Caco2 cells. HCECs showed no PARP cleavage following target
knockdown, whereas HCT116 and Caco2 cells demonstrated PARP cleavage upon
KSR1 or EPHB4 depletion (Fig 3.4). These observations show that KSR1 and EPHB4
are selectively required for colon tumor cell survival and growth and suggest that without
KSR1 or EPHB4 cells undergo apoptosis.
Downstream effectors of KSR1-dependent signaling in colon tumor cell lines
include the RAF/MEK/ERK kinase cascade and PGC1 family of transcriptional regulators
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Fig 3.2 Depletion of KSR1 or EPHB4 is selectively toxic to CRC cells.
Viability of HCEC, HCT116, and Caco2 cells was measured following RNAi of KSR1 or
EPHB4 by alamarBlue® assays. Data are shown as mean fluorescent intensity ± SD.
****p<0.0001 (matched two-way ANOVA, Dunnett’s post-test for multiple comparisons).
Validation of target knockdown at 72 h is shown by western blot below.
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Fig 3.3 Depletion of KSR1 or EPHB4 inhibits anchorage-independent growth.
Viability of HCT116 and Caco2 cells was measured following RNAi of KSR1 or EPHB4
in anchorage-independent conditions by CellTiter-Glo® assays. Data are shown as
relative light units (RLU) ± SD. ****p<0.0001 (matched two-way ANOVA, Dunnett’s posttest for multiple comparisons). Validation of target knockdown at 48 h timepoint is shown
by western blot below.
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Fig 3.4 KSR1 and EPHB4 depletion selectively induces apoptosis in CRC cells.
PARP cleavage was measured by western blot following depletion of KSR1 or EPHB4
for 72 h in HCEC, HCT116, and Caco2 cells.
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(166, 172, 180, 187, 188). We recently identified PGC1β as a key downstream effector
of KSR1 in human colon tumor cells and showed that its expression is required for colon
cancer survival both in vitro and in vivo (188). To determine whether EPHB4 disrupts
either of these pathways, we assessed MEK1/2 and ERK1/2 activation and total PGC1β
protein levels by western blot after 72 hours of EPHB4 depletion in HCT116 and Caco2
cells. We observe that depletion of EPHB4 does not affect MEK1/2 or ERK1/2
phosphorylation. However, EPHB4 RNAi does suppress PGC1β levels (Fig 3.5). These
data suggest that EPHB4 is acting as a functional analog of KSR1 to regulate PGC1β.

Inhibition of EPHB4 kinase activity is selectively toxic to colon tumor cells
Currently, there are several clinical trials in various cancers involving the
pharmacological targeting of EPHB4 (250, 251). One strategy for targeting EPHB4 is
inhibition of its kinase activity. To test whether this, like RNAi-mediated EPHB4
depletion, is selectively toxic to colon tumor cells, we treated HCECs and a panel of
colon tumor cell lines with increasing doses of an EPHB4 kinase inhibitor, AZ12672857
(AZ2857), for 72 hours and cell viability was measured using CellTiter-Glo®. The EC50
for each cell line was determined from four independent experiments using a non-linear
curve fit with a variable slope (Fig 3.6A, Drew Gehring). HCECs (EC50 = 14 µM) were
less sensitive to EPHB4 inhibition than HCT116 or Caco2 cells, 3.2 µM and 2.6 µM,
respectively. The EC50 of three additional colon tumor cell lines (SW480, DLD1, and SKCO-1) are shown in the table of Fig 3.6A (Drew Gehring). HCECs tolerated doses up to
20 µM (highest tested) without increasing the percentage of PI-stained cells in the subG1 peak when measured by flow cytometry (Fig 3.6B, Drew Gehring). However, at the
same dose, HCT116 and Caco2 cells had >50% sub-G1 cells after 72 hours of treatment
with AZ2857. Taken together, these data indicate that inhibition of EPHB4 decreases
total ATP levels as measured by the CellTiter-Glo® cell viability assay in the HCECs,
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Fig 3.5 Depletion of EPHB4 decreases PGC1β expression, but not MEK and ERK
activation.
EPHB4 was depleted by siRNA for 72 h in HCT116 cells. Protein expression was
measured by western blot. (Experiment performed by Kurt Fisher)
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Fig 3.6 EPHB4 inhibitors are selectively toxic to colon tumor cell lines.
HCEC, Caco2, HCT116, SW480, DLD1, and SK-CO-1 cells were treated with increasing
doses of AZ12672857 and cell viability was measured by CellTiter-Glo® at 72 hours.
Each data point represents four independent experiments. Data are presented as mean
± SEM. Data were normalized and the EC50 for each cell line was calculated using an
algorithm for fitting a non-linear curve with variable slope in GraphPad Prism. (B) HCEC,
HCT116, and Caco2 cells were treated with increasing doses of AZ12672857. The subG1 peak was quantified following PI staining and analysis by flow cytometry.
(Experiments performed by Drew Gehring)
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possibly through reduced growth or induction of senescence, but that treatment with
AZ2857 does not induce apoptosis. However, in the tumor cell lines, HCT116 and
Caco2, treatment with AZ2857 clearly reduces cell viability via induction of cell death.

KSR1 and EPHB4 regulate Myc and PGC1β
Previous research demonstrated that Myc regulates PGC1β transcription in renal
cell carcinoma (261) and breast cancer cells (260). Therefore, we examined whether
Myc regulates PGC1β in colon tumor cell lines. In HCT116 and Caco2 cells, Myc was
depleted with a pool of siRNA; PGC1β protein levels were decreased with Myc
knockdown as assessed by western blot (Fig 3.7A). To determine if this effect was due
to a single siRNA and potentially an off-target effect, the four siRNA duplexes (duplexes
22, 23, 24, and 25) that compose the pool were assessed independently. Expression of
PGC1β protein correlated with degree of Myc knockdown (Fig 3.7B). The pool of all four
siRNA duplexes was used in the following experiments. Next, PGC1β mRNA levels were
measured by RT-qPCR following depletion of Myc. In both HCT116 and Caco2 cells,
Myc depletion significantly decreased expression of PGC1β mRNA (Fig 3.8). Expression
of Myc is required for the formation of intestinal crypts, but is dispensable for
homeostasis of the adult epithelium (293). To evaluate the importance of Myc
expression to CRC cell viability, two tumor cell lines (HCT116 and Caco2) and one
normal colon cell line (HCECs) were transfected with siMyc or a non-targeting siRNA
and cell viability was assessed 72 hours post-transfection. Depletion of Myc reduced cell
viability in HCT116 (60%) and Caco2 (64%) cells, but did not affect growth in the HCECs
(Fig 3.9), indicating that the tumor cells are more reliant on the expression of Myc for cell
growth. Validation of target knockdown is shown by western blot.
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Fig 3.7 Myc regulates PGC1β in colon tumor cells.
(A) Western blot following RNAi of Myc in HCT116 (left) and Caco2 (right) cells. (B) Myc
and PGC1β protein expression in HCT116 cells transfected with individual or pooled (all
4) Myc siRNA duplexes.
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Fig 3.8 Myc depletion reduces PGC1β mRNA levels in CRC cells.
RNA levels of Myc and PGC1β were measured by RT-qPCR in HCT116 (left) and Caco2
(right) cells following RNAi of Myc. Data are shown as mean ± SD. *p<0.05, **p<0.01,
***p<0.001 (paired, two-tailed t-test).
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Fig 3.9 Myc depletion decreases viability in colon tumor cell lines.
Cell viability was measured by alamarBlue® following depletion of Myc. Data are shown
as mean ± SD. ***p<0.001 (matched, two-way ANOVA).
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To determine whether KSR1 and EPHB4 are regulating PGC1β through a Mycdependent pathway, we assessed Myc and PGC1β protein levels following depletion of
KSR1 or EPHB4 resulted in diminished expression of Myc and PGC1β (Fig 3.10A), with
EPHB4 depletion having the greatest effect on Myc levels. To confirm that these data
are not the result of a single siRNA or an off-target effect, we transfected the four
individual siRNA duplexes for KSR1 (Fig 3.10B) and EPHB4 (Fig 3.10C) into HCT116
cells and measured target, Myc, and PGC1β protein expression by western blot 72
hours post-transfection. With the exception of KSR1 siRNA 6, all individual duplexes
sufficiently depleted the expression of their target as well as Myc and PGC1β. Due to its
lack of target knockdown, the KSR1 siRNA duplex 6 was not used in the siKSR1 pool in
any experiment. Additionally, HCT116 and Caco2 cells were treated with increasing
doses of the EPHB4 kinase inhibitor, AZ2857, for 72 hours. Western blots indicate that
pharmacological inhibition of EPHB4 decreases Myc and PGC1β protein levels similar to
that seen with depletion using siRNA (Fig 3.11A, Drew Gehring). HCT116 cells were
treated with 10 µM AZ2857 for 0-72 hours and total levels of Myc and ERK activation
were assessed by western blot. Inhibition of EPHB4 reduced Myc levels in an ERKindependent manner (Fig 3.11B).
To assess whether EPHB4 also regulates PGC1β mRNA levels, HCT116 and
Caco2 cells were transfected with siRNA targeting EPHB4 (or a non-targeting siRNA) or
treated with 10 µM of AZ2857 for 72 hours. Myc and PGC1β mRNA levels were
measured by RT-qPCR. Data from three biological replicates (each measured in
triplicate) are shown in Fig 3.12A (siRNA) and Fig 3.12B (EPHB4 inhibitor). Depletion of
EPHB4 by siRNA decreased Myc and PGC1β mRNA expression by 46% and 49% in
HCT116 and 70% and 26% (not significant) in Caco2 cells, respectively. Inhibition of
EPHB4 with the kinase inhibitor AZ2857 consistently decreased levels of both Myc and
PGC1β mRNA 70% and 45% in HCT116 and 67% and 56% in Caco2, respectively.
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Fig 3.10 Inhibition of KSR1 or EPHB4 decreases Myc and PGC1β protein levels.
Myc and PGC1β protein levels were assessed by western blotting following RNAi of
KSR1 or EPHB4 in HCT116 (left) and Caco2 (right) cells. (B) Individual siRNA duplexes
for KSR1 (top) and EPHB4 (bottom) were transfected into HCT116 cells and Myc and
PGC1β protein expression was assessed by western blot. The KSR1 pool contains
duplexes 7-9. The EPHB4 pool contains all 4 siRNA duplexes.
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Fig 3.11 Treatment with EPHB4 kinase inhibitor decreases Myc protein levels.
Myc and PGC1β protein levels were assessed by western blotting following treatment
with AZ12672857 (AZ2857), an EPHB4 inhibitor in HCT116 (left) and Caco2 (right) cells.
(B) Myc, phospho-ERK, and total ERK1/2 protein levels were assessed by western
blotting following treatment of HCT116 with 10 µM AZ2857 for 0-72 h. (Experiment
3.11A performed by Drew Gehring)
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Fig 3.12 EPHB4 inhibition decreases Myc and PGC1β mRNA expression.
RNA levels of Myc (top) and PGC1β (bottom) were measured by RT-qPCR in HCT116
(left) and Caco2 (right) cells following RNAi of EPHB4 (A) or treatment with AZ2857 (B).
Data are shown as mean ± SD. *p<0.05, **p<0.01 (A) repeated measures, one-way
ANOVA with Dunnett’s post-test for multiple comparisons; (B) paired, two-tailed t-test.

56

Depletion of KSR1 did not affect mRNA levels of Myc or PGC1β (Fig 3.12A). These
observations suggest that EPHB4 may regulate PGC1β transcription in a Mycdependent manner. Although EPHB4 was identified by FUSION using KSR1 as a
reference standard, and both proteins share common downstream effectors (Myc and
PGC1β), these data reveal that the mechanisms by which EPHB4 and KSR1 regulate
Myc and PGC1β are not identical.

KSR1 and EPHB4 do not affect Myc stability
One mechanism by which Myc protein stability is regulated is through
proteasome-mediated degradation by F-box and WD repeat domain-containing 7
(FBW7)-containing Skp1-Cul1-Fbox (SCF) ubiquitin ligase (277). FBW7 is frequently
deleted or mutated in a variety of cancers including gastric (294), colon (280, 295), and
breast (296). In contrast, FBW7 is rarely mutated in pancreatic cancer, but the protein is
significantly downregulated by activated Ras-RAF-MEK-ERK signaling (297). ERKdependent phosphorylation of FBW7 leads to ubiquitination and proteasome-mediated
degradation by an undefined E3 ligase resulting in elevated expression of FBW7
substrates, such as Myc (297). On the basis of these observations, we tested whether
depletion of KSR1 or EPHB4 increased the amount of FBW7 in the colon cancer cell
line, HCT116, which expresses FBW7 (298). Since KSR1 is necessary for maximal ERK
phosphorylation and subsequent activation (166), we anticipated that depletion of KSR1
would increase cellular levels of FBW7. However, as shown in Fig 3.5 and 3.11B,
depletion of EPHB4 does not affect phosphorylation of MEK or ERK. Therefore, we
predicted that depletion of EPHB4 would not enhance FBW7 levels in the HCT116 cells.
As anticipated, FBW7 is significantly upregulated in HCT116 cells upon KSR1 depletion.
However, it is also upregulated by EPHB4 depletion, although to a lesser degree than
KSR1 depletion (Fig 3.13). Another SCF ubiquitin ligase, SCFβ-TrCP, targets an alternate
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Fig 3.13 Depletion of KSR1 or EPHB4 increases FBW7 expression in HCT116 cells.
Expression of the E3 ubiquitin ligases FBW7 and β-TrCP were assessed by western blot
after knockdown of KSR1 or EPHB4.
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phosphodegron at Ser279 and Ser283 to ubiquitinate and stabilize Myc (299). We,
therefore, tested the expression of β-TrCP following KSR1 or EPHB4 depletion.
Expression of β-TrCP was unchanged in either condition (Fig 3.13).
FBW7-dependent degradation of Myc is dependent on consecutive
phosphorylation at Ser62, then Thr58 (277, 300). Phosphorylation at these sites exhibit
opposing roles, with Ser62 promoting Myc stability and Thr58 promoting
ubiquitin/proteasome-dependent degradation by FBW7 (277, 300, 301). In the absence
of Ser62 phosphorylation, Myc protein is rapidly degraded by one of several FBW7independent mechanisms (277, 302). To determine if depletion of KSR1 or EPHB4 is
promoting Myc degradation by mediating phosphorylation of either of these sites, we
assessed Myc phosphorylation following proteasome inhibition with MG132 using
phospho-specific antibodies. The ratio of phosphorylated to total Myc after MG132
treatment was quantified in three independent experiments (Fig 3.14). While levels of
Thr58 phosphorylation remained unchanged and highly variable, phosphorylation at
Ser62 was consistently decreased in KSR1- and EPHB4-depleted cells indicating that
KSR1- or EPHB4-dependent phosphorylation of Myc at Ser62 contributes to the
stabilization of Myc.
We further assessed the role of KSR1 and EPHB4 in FBW7-dependent
regulation of Myc using HCT116 cells with genetic deletion of FBW7 (298). Myc and
PGC1β protein levels were assessed in the presence and absence of KSR1 or EPHB4.
Knockdown of KSR1 or EPHB4 resulted in decreased Myc and PGC1β protein even in
the absence of FBW7 (Fig 3.15). Taken together, these data suggest that although
KSR1 and EPHB4 can augment FBW7 levels and increase phosphorylation of Myc at
Ser62, these proteins primarily regulate Myc expression by an FBW7-independent
mechanism and further suggest the possibility that an additional E3 ligase recognizing
Myc phosphorylation at Ser62.
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Fig 3.14 Depletion of KSR1 or EPHB4 decreases Myc phosphorylation at Ser62 in
HCT116 cells.
Expression of phosphorylated and total Myc following KSR1 or EPHB4 depletion in the
presence or absence of MG132 was assessed by western blot. Phospho-Myc
expression was quantified and normalized to total Myc. Quantification of three replicates
(mean ± SD) is shown in the graph below.
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Fig 3.15 Depletion of KSR1 or EPHB4 decreases Myc stability in WT and FBW7-/HCT116 cells.
Myc and PGC1β protein expression is assessed by western blot following KSR1 or
EPHB4 depletion in WT and FBW7-/- HCT116 cells.
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To test the hypothesis that depletion of KSR1 or EPHB4 is affecting Myc levels
by regulating protein stability, we examined the turnover of Myc in HCT116 cells
following treatment with CHX with and without RNAi of KSR1 or EPHB4. Representative
western blots of HCT116 cells from three independent experiments are shown (Fig
3.16A). Data from three independent experiments in each cell line was quantified and
the half-life of Myc in each condition was calculated using GraphPad Prism software.
Depletion of KSR1 or EPHB4 did not change the rate of Myc turnover (Fig 3.16B).

KSR1 promotes the translation of Myc
Regulation of protein synthesis is mediated by key inhibitors of translation,
eukaryotic initiation factor 4E binding protein 1 (4E-BP1) and programmed cell death 4
(PDCD4) [reviewed in (303)]. 4E-BP1 sequesters eukaryotic initiation factor 4E (eiF4E)
to inhibit translation. Phosphorylation of 4E-BP1 releases eIF4E and de-represses
protein synthesis [reviewed in (303)]. Similarly, PDCD4 sequesters eukaryotic initiation
factor 4A (eIF4A). Phosphorylation of PDCD4 leads to its nuclear localization or
proteasome-mediated degradation (304). PDCD4 can be phosphorylated by p70 S6
kinase (S6K) or p90 ribosomal protein S6K (RSK) (304, 305). 4E-BP1 and eIF4E
regulate cap-dependent translation, while PDCD4 and eIF4A regulate both capdependent and –independent translation [reviewed in (303)].
To determine if KSR1 or EPHB4 affects the expression of these key regulators of
protein synthesis, KSR1 and EPHB4 were depleted by siRNA for 48 hours in HCT116
and Caco2 cells. In both cell lines, depletion of KSR1, but not EPHB4, decreased 4EBP1 and eIF4E phosphorylation (Fig 3.17). This suggests that depletion of KSR1 inhibits
cap-dependent translation. Additionally, depletion of KSR1, and not EPHB4, increased
the total levels of PDCD4, suggesting that KSR1 can promote both cap-dependent and
cap-independent translation.
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Fig 3.16 Depletion of KSR1 or EPHB4 does not affect Myc stability in HCT116 or
Caco2 cells.
Depletion of KSR1 or EPHB4 performed for 72 hours prior to treatment with 100 µg/mL
CHX or vehicle for 0, 15, 30, 45, 60, or 75 minutes. Myc levels were assessed by
western blot (A). Assay was performed three times in each cell line. Myc expression was
quantified and normalized to β-actin. Myc half-life was calculated using a non-liner, onephase decay (Y0 = 100, plateau = 0) with automatic outlier elimination in GraphPad
Prism (B).
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Fig 3.17 Depletion of KSR1 affects key inhibitors of protein translation.
HCT116 and Caco2 cells were transfected with siRNA targeting KSR1 or EPHB4, or a
non-targeting siRNA (Cont) for 48 hours. Protein expression levels were assessed by
western blot.
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We further assessed the role of KSR1 and EPHB4 in Myc translation using
luciferase reporter constructs containing the Myc 5’ UTR. The 5’ UTR of Myc mRNA
contains an internal ribosome entry site (IRES) (230), and therefore Myc is translated in
both a cap- and IRES-dependent manner. Translation from the IRES element depends
on eIF4A (helicase), but is independent of eIF4E (cap binding protein) (306). First, we
measured total translation of Myc (cap- and IRES-dependent) using the pGML reporter
construct (231, 307), which contains the entire 5’ UTR of Myc. Luciferase signal was
normalized to total protein in each sample. Depletion of KSR1, but not EPHB4,
decreased translation of Myc in HCT116 and Caco2 cells by 49% and 33%, respectively
(Fig 3.18). Since KSR1 also affected the expression of PDCD4, we also measured the
effect of KSR1 depletion on IRES-dependent translation of Myc. Depletion of KSR1
decreases IRES-dependent Myc translation in HCT116 and Caco2 cells by 63% and
68%, respectively (Fig 3.19).
To determine the relative contribution of IRES-dependent translation of Myc to
total Myc synthesis, HCT116 and Caco2 cells were transfected with pGML (Myc 5’
UTR), phpL (hairpin only), or phpmL (hairpin-Myc 5’ UTR) luciferase reporter constructs
with a pSV-β-galactosidase vector for 24 hours. Luciferase expression was normalized
to β-galactosidase expression in each well. IRES-dependent translation comprises 32%
and 14% of total Myc translation in HCT116 and Caco2 cells, respectively (Fig 3.20).

KSR1 protects EPHB4 from lysosome-dependent degradation
To assess the possible relationships between KSR1 and EPHB4, KSR1 and
EPHB4 were depleted by siRNA for 72 hours in HCT116 and Caco2 cells. Levels of
KSR1 and EPHB4 protein (Fig 3.21A) and mRNA (Fig 3.21B) were measured by
western blot and RT-qPCR, respectively. Depletion of KSR1 results in a consistent
reduction in EPHB4 protein expression, but not mRNA levels. EPHB4 knockdown does
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Fig 3.18 KSR1 promotes the translation of Myc protein.
HCT116 and Caco2 cells were depleted of KSR1 or EPHB4 for 24 hours and then
transfected with the pGML (Myc 5’ UTR) luciferase reporter construct for an additional
24 hours. Luciferase expression was normalized to total protein in each well. Data are
shown as mean ± SD. *p<0.05, **p<0.01 (repeated measures, one-way ANOVA with
Dunnett’s post-test for multiple comparisons).
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Fig 3.19 KSR1 promotes IRES-dependent translation of Myc.
HCT116 and Caco2 cells were depleted of KSR1 for 24 hours and then transfected with
the phpmL (hairpin-Myc 5’ UTR) luciferase reporter construct for an additional 24 hours.
Luciferase expression was normalized to total protein in each well. Data are shown as
mean ± SD. *p<0.05 (paired, tailed t-test).
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Fig 3.20 IRES-dependent translation accounts for a portion of total Myc
translation.
HCT116 and Caco2 cells were transfected with pGML (Myc 5’ UTR), phpL (hairpin only),
or phpmL (hairpin-Myc 5’ UTR) luciferase reporter constructs with a pSV-βgalactosidase vector for 24 hours. Luciferase expression was normalized to βgalactosidase expression in each well. Data are shown as technical replicates of a single
biological replicate.
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Fig 3.21 Depletion of KSR1 decreases EPHB4 protein, but not mRNA, expression.
KSR1 or EPHB4 was depleted in HCT116 and Caco2 cells for 72 h. (A) KSR1 and
EPHB4 protein levels were assessed by western blot. (B) KSR1 and EPHB4 mRNA
levels were measured by RT-qPCR. Data are shown as mean ± SD. *p<0.05, ***p<0.001
(repeated measures, one-way ANOVA with Dunnett’s post-test for multiple
comparisons).
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not affect KSR1 protein or mRNA expression in either cell line. This suggests that KSR1
regulates EPHB4 protein levels via a post-transcriptional mechanism.
KSR1 regulates proteins, such as Myc and PGC1β, which are degraded by the
proteasome (188, 308). Therefore, we tested whether KSR1 depletion induces
proteasome-mediated degradation of EPHB4. HCT116 and Caco2 cells were depleted
of KSR1 for 72 hours and incubated with and without 10 µM MG132 for the final 6 hours
of knockdown. Treatment with MG132 was unable to rescue the EPHB4 levels when
KSR1 was depleted (Fig 3.22). Inhibition of proteasomal degradation of Myc was used
as a positive control for MG132 treatment. In HCT116 cells without KSR1 depletion,
MG132 treatment increases EPHB4 expression suggesting that EPHB4 degradation is
partially mediated by the proteasome in these cells, but the effect of KSR1 on EPHB4
stability is independent of proteasome-mediated degradation.
A canonical method of RTK signal termination is downregulation after ligand
binding (309-311). Lysosome-mediated degradation of RTKs, including EPHB1, has
been well documented (312-314). We assessed whether EPHB4 degradation is
mediated by the lysosome and whether KSR1 stabilizes EPHB4 expression by
suppressing this degradation. KSR1 was depleted in HCT116 and Caco2 cells for 72
hours with and without treatment with 100 nM bafilomycin A1 (BafA1), an inhibitor of
autophagosome-lysosome fusion, for the final 8 hours of knockdown. Treatment with
BafA1 alone increased the expression of EPHB4 in both HCT116 and Caco2 cells (Fig
3.19). Additionally, when cells were depleted of KSR1, treatment with BafA1 rescues
EPHB4 expression. Increased LC3BII and p62 expression are used as positive controls
for BafA1 treatment. Taken together, these data indicate that KSR1 stabilizes EPHB4 by
suppressing lysosome-mediated degradation.
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Fig 3.22 EPHB4 expression is not rescued by proteasomal inhibition with MG132.
KSR1 was depleted in HCT116 and Caco2 cells for 72 h. Cells were treated with and
without 10 µM MG132 for the last 8 h of knockdown. Proteins were analyzed by western
blot. Myc is used as a positive control for MG132 treatment.
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Fig 3.23 KSR1 expression protects EPHB4 from lysosome-dependent degradation.
KSR1 was depleted in HCT116 and Caco2 cells for 72 h. Cells were treated with and
without 100 nM Bafilomycin A1 (BafA1) for the last 8 h of knockdown. Proteins were
analyzed by western blot. LC3B and p62/SQSTRM are used as positive controls for
BafA1 treatment.
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Discussion
Here we identify a new pathway critical for colon tumor cell survival impacted by
effectors of Ras and Wnt signaling. Two proteins, KSR1 and EPHB4, are required for
increased Myc protein expression in human colon tumor cells, which then promotes the
expression of its downstream effector PGC1β (Fig 3.24). We recently showed that Rasinduced and KSR1-dependent PGC1β upregulation is required for colon cancer survival
in vitro and in vivo (188). Here, we show that KSR1- and EPHB4-dependent
mechanisms increase and stabilize Myc expression, which drives PGC1β expression in
colon tumor cell lines to promote their survival.
Using KSR1 as a reference standard, we used FUSION (188, 228) to identify
EPHB4 as a gene that is required for colon tumor cell survival. The mechanistic role that
EPHB4 plays in cancer remains controversial. However, a preponderance of data
indicates that EPHB4 is overexpressed broadly in human cancers including cancers of
the head and neck, prostate, bladder, ovaries, large intestine, lung, brain, pancreas, and
the esophagus (269, 271, 284-290). Further research has shown that the ablation or
inhibition of EPHB4 in a number of cancer cell types reduces tumor cell viability
including: prostate (315), bladder (286), ovarian (269), colon (271), lung (287), head and
neck squamous cell carcinoma (316), and esophageal (290). Additionally, patient data
have shown that EPHB4 levels negatively correlate with overall patient survival in
ovarian cancer and glioblastoma (269, 288).
Expression of EPHB2 and EPHB4 is regulated by Wnt/β-catenin signaling in
human CRC (271, 317). β-catenin’s binding partners, p300 and CBP, determine which
gene is transcribed, with p300 promoting EPHB2 expression and CBP promoting EPHB4
(271). EPHB2 is present in the normal colon and EPHB4 is only expressed when tumors
arise (271). These data contrast with previous studies showing that EPHB4 is expressed
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Fig 3.24 Model of MEK/ERK-dependent regulation of Myc and PGC1β expression
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in human colonic crypts and early CRC lesions (318) followed by promoter
hypermethylation and epigenetic silencing in more advanced stages (319). These data
also indicate that EPHB4 expression is highest at the bases of crypts, suggesting that it
plays an important role in maintaining the population of stem and progenitor cells located
in that region of the crypt (318). The repulsive interaction that occurs when the ephrinB2
ligand-expressing cells of the upper region of the crypt come in contact with the EPHB4
receptor-expressing cells located at the base of the crypt suggests that this expression
pattern may aid in compartmentalizing tumor cells and reducing the dissemination of
such cells; in these studies, EPHB4 is functioning as a tumor suppressor (318, 320-322).
While controversial, the majority of studies support the idea that increased EPH forward
signaling promotes cell segregation and is primarily tumor-suppressive, whereas reverse
signaling through the ephrin ligand is tumor-promoting driving neoangiogenesis and
invasion (321, 323). However, further data suggest that ligand-independent forward
signaling when EPHB4 is overexpressed promotes tumorigenesis, while ephrinB2dependent activation is tumor suppressing (324, 325). Additionally, EPHB forward
signaling can also be cross-activated by FGFR and ERBB receptors leading to noncanonical forward signaling that promotes cell proliferation (251), thereby contributing to
tumorigenesis.
We show that EPHB4 is overexpressed in a panel of colon tumor cell lines and,
like KSR1, EPHB4 depletion via siRNA or small-molecule inhibition is selectively toxic to
colon tumor cells as compared to immortalized, but non-transformed HCECs. The
mechanism of HCEC resistance to EPHB4 inhibition may result from the fact that
EPHB4 expression is minimal in this cell line and the cells do not rely on its
overexpression for survival. These data are consistent with previous studies showing
that EPHB4 is absent in normal colon, but is expressed in all 102 human colorectal
cancer sections analyzed by both immunohistochemistry and RT-qPCR (271).
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Recent work from The Cancer Genome Atlas (TCGA) Network discovered that,
in a comprehensive examination of human colon and rectal cancers of diverse
anatomical origin and mutation status, changes in Myc transcriptional targets were found
in nearly 100% of the tumors (280), suggesting an important role for Myc in CRC. While
a promising target for CRC, Myc is a transcription factor and traditionally considered
“undruggable” (262, 281). Although there are new strategies emerging to inhibit Myc,
including interrupting key dimerization events or DNA binding (262), finding additional or
alternative ways to target Myc protein expression or its downstream effectors may
provide therapeutic benefits to many cancer patients.
Our studies show that EPHB4 regulates Myc expression through the promotion
of mRNA levels. However, KSR1 does not share this mechanism of action, which led us
to examine alternative explanations for its ability to increase Myc levels in human colon
tumor cells. Further analyses of post-transcriptional mechanisms suggest that KSR1
promotes the translation of Myc. Myc mRNA can be translated into protein under
conditions where initiation from the 5’ cap structure and ribosome scanning is inhibited.
Previous work has shown that, following hypoxia, PGC1β mRNA is decreased in
renal clear cell carcinoma cells that is caused by an induction of MXI1, a repressor of
Myc activity (261). Further work demonstrated that Myc regulates HER2- and IGF1dependent induction of PGC1β in breast cancer cells (260). Our work indicates that Myc
also mediates EPHB4 and KSR1 regulation of PGC1β expression. Combined with these
reports, our work suggests that tumor cells of diverse origins find multiple ways to
regulate Myc-driven PGC1β expression.
Lysosomal degradation of RTKs is well documented (326). Here we show that
EPHB4 is primarily degraded via the lysosome and that KSR1 depletion promotes that
degradation. Canonical lysosomal RTK degradation occurs following activation of the
receptor by its respective ligand. However, ligand-independent receptor degradation has
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been reported (327, 328). Mechanisms involved in KSR1-dependent regulation of
EPHB4 have not been explored further. However, it is anticipated that KSR1-dependent
effects on Myc and PGC1β are not simply due to KSR1 stabilizing EPHB4. This
prediction is based on the differential effects (transcriptional versus post-transcriptional
regulation of Myc expression) observed with KSR1 and EPHB4 depletion. However, the
observation that KSR1 can promote the stability of RTKs may allude to a broader
mechanism by which KSR1 supports tumorigenesis.
The identification of these relationships highlights an important aspect of
FUSION. Although the screen was intended to identify genes whose knockdown
mimicked that of KSR1 depletion in a Ras-mutated cell line, it is designed in a way that
focuses on phenotype, which does not necessarily require direct effects on KSR1specific pathways. Therefore, we can identify critical effectors, such as EPHB4, whose
inhibition has the same effect as depletion of KSR1, but whose mechanism of action is
different. Additionally, although the cell line used in our screen (HCT116) has activated
Ras, this study indicates that we have and can identify vulnerabilities in cancer tumor
cells that are independent of constitutively activated Ras pathways. This may lead to the
identification of potential targets that are applicable in a wide variety of cancer cell types.
Here we highlight the benefits of using an unbiased screen and FUSION analysis
to identify potential vulnerabilities present only in cancer cells that are not found in
normal cells. In fact, the identification of EPHB4 as a novel effector of Myc signaling
prompted us to evaluate the relationship between KSR1 and Myc, establishing that the
identification of targets using FUSION can also reveal novel information about KSR1 as
well. We demonstrate novel mechanisms by which KSR1 and EPHB4 regulate PGC1β
via promotion of Myc translation and mRNA expression, respectively. While the
regulation of PGC1β by Myc has been previously studied in renal cell carcinoma (261)
and breast cancer cells (260), we show that this pathway is present in and critical for
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colon cancer cell survival. Taken together, these data reveal that tumor cells in various
cancers have a unique dependence on Myc-dependent expression of PGC1β for cell
survival, which may be exploited in the development of new cancer therapeutics.
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Chapter 4: PGC1β expression is promoted by ERK and
inhibited by HSF1
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Introduction
Heat shock factors (HSFs) are a small group of transcription factors that regulate
the heat shock response (HSR). There is a single HSF in yeast, worms, and flies, but
four HSFs (HSF1, 2, 3, 4) in mammals, of which HSF1 is the master regulator of HSR
[reviewed in (329)]. HSR is a highly conserved, protective mechanism that manages
environmental stresses, promotes survival, and regulates the longevity of the organism.
Following exposure to certain stresses, HSF1 is activated to induce a group of proteins
known as the heat shock proteins (HSPs) (330, 331). Activation of HSF1 is a multi-step
process consisting of trimerization, extensive post-translational modifications (including
phosphorylation, acetylation, and sumoylation), nuclear translocation, DNA-promoter
binding, and induction of transcriptional targets (including Hsps) [reviewed in (329)]. In
addition to the classical induction of the heat shock response, HSF1 has been shown to
regulate up to 3% of the yeast genome including genes functioning in energy production
and signal transduction (332).
HSF1 is a potent modifier of tumorigenesis and is required for tumor initiation and
maintenance in a variety of cancer models (333). HSF1 is dispensable under non-stress
conditions, but crucial for growth and survival in tumor cells (333). Elevated levels of
HSF1 have been detected in several types of cancer including cancers of the breast,
lung, and colon (333, 334), but no somatic mutations in HSF1 have been identified in
human cancers thus far. Additionally, HSF1 drives a transcriptional program distinct from
the HSR to upregulate cancer-specific genes and support oncogenic processes such as
cell cycle regulation, signaling, metabolism, adhesion, and translation (334). The HSF1
cancer-specific transcriptome signature was found to be associated with increased
metastasis and reduced survival in lung, breast, and colon cancer patients (334).
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Unlike mutant Ras, overexpression of HSF1 is unable to transform immortalized
MEFs (333). Conversely, MEFs lacking hsf1 are resistant to transformation induced by
oncogenic H-RasV12D or PDGF-B (333). Additionally, mice deficient in HSF1 exhibit a
lower incidence of tumors and increased survival as compared to their wild-type controls
both in a model of chemical skin carcinogenesis, as well as in a genetic model
expressing oncogenic p53 (335). HSF1 expression in tumor cells is a prime example of
“non-oncogene addiction” (336). While not every protein in a given tumor-promoting
pathway can be activated to an extent that directly promotes oncogenesis, they can be
rate limiting within their pathways and represent potential drug targets. These potential
targets are important because they represent approaches to treat cancers that are not
dependent on traditional oncogenes.
A recent publication has identified HSF1 as a new substrate of MEK1/2 (335).
Using a combination of inhibitors and mutant constructs, they show that phosphorylation
of HSF1 on Ser326 stabilizes HSF1 protein and is dependent on the activity of MEK1/2,
but not ERK1/2, in NIH 3T3 and HEK293T cells. In vitro kinase activity assays were
used to demonstrate that increasing doses of a MEK inhibitor (U0126) were sufficient to
inhibit phosphorylation of HSF1 at Ser326, whereas increasing doses of the ERK
inhibitor (FR180204) were not. Additionally, inhibition of MEK1/2 significantly decreased
direct binding of HSF1 to DNA in the presence and absence of heat shock suggesting
that MEK1/2 can directly regulate the HSF1-driven transcriptional program regardless of
heat shock/cellular stressors.
The canonical substrate of MEK1/2 is ERK1/2. MEK1/2 catalyzes the
phosphorylation of human ERK1/2 at Tyr204/187 and Thr202/185 (125). ERK1/2dependent signaling regulates a variety of processes including cell adhesion, cell cycle
progression, migration, survival, differentiation, metabolism, proliferation, and
transcription (105). Human ERK1 and ERK2 are 84% identical and share many functions
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(129), but are not entirely redundant (132). The erk1 gene is dispensable for mouse
development. erk1-/- mice are deficient in thymocyte maturation and, therefore, normal Tcell effector function, but are viable, fertile, and are normal in size (130, 131). Ablation of
erk2 is embryonic lethal (132).
ERK1 and ERK2 have more than 175 documented cytoplasmic and nuclear
substrates (337). In the nucleus, they can target the ternary complex factor (TCF) family
of transcription factors, including the E-twenty six (Ets)-domain transcription factor Elk1.
These play a role in inducing the expression of immediate early genes, which encode cFos and c-Myc. c-Myc and c-fos induce the expression of late-response genes that
promote cell survival, division, and motility (169, 338). In the cytoplasm, ERK1/2 have a
variety of substrates including c-Myc (as described in Chapter 3) and the 90-kDa
ribosomal S6 kinase (RSK) family of proteins (339). RSK proteins contain two kinase
domains, an N-terminal kinase domain (NTKD) or C-terminal kinase domain (CTKD)
within a single polypeptide chain (339). The CTKD is involved in the autophosphorylation
of RSK proteins, while the NTKD is important in substrate phosphorylation. ERK1/2
phosphorylates RSK at Thr573 in the CTKD activation loop, which subsequently
catalyzes the phosphorylation of Ser380 (339). Regardless of substrate, ERK1/2
catalyze the phosphorylation of serine or threonine residues in a proline-directed manner
(127). The optimal primary sequence for ERK1/2 phosphorylation is Pro-X-Ser/Thr-Pro
with a proline at both the -2 and +1 positions (127).
Small-molecule inhibitors of ERK1/2 have been developed with varying success.
Two main strategies have been employed: ATP mimetic inhibitors that target the active
kinase (type-I inhibitors) such as FR180204 and VTX-11e, and inhibitors that target and
stabilize the inactive state of an enzyme (type-II inhibitors) (224). Selectivity is a
challenge for type-II inhibitors as they target a more diverse range of structures. Ideally,
one would use non-ATP-based allosteric inhibitors because they are usually highly
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selective (210, 340). Recently a highly potent and selective ERK1/2 inhibitor was
identified (224). This inhibitor does not bind to the “active” or “inactive” conformation of
ERK1/2, but rather induces an allosteric site adjacent to the ATP pocket in which it binds
(226). This inhibitor also has a slow dissociation rate allowing its effects to remain after
the drug has been washed out making it an ideal inhibitor to use both in vitro and in vivo
(226).
Peroxisome proliferator-activated receptor γ (PPARγ) coactivator 1 (PGC1)
family members, PGC1α, PGC1β, and PGC1-related coactivator (PRC), are
transcriptional coactivators that serve as inducible coregulators of nuclear receptors that
control cellular energy via metabolic pathways (341). PGC1α was first identified in brown
adipose tissue (BAT) through its functional interaction with the nuclear receptor PPARγ
during thermogenesis (342). PGC1β and PRC were subsequently identified to regulate
PPARγ-dependent transcription (343-345). In addition to PPARγ, PGC1 coactivators
enhance the transcriptional activity of a variety of nuclear receptors, including liver X
receptor (LXR) (346) and estrogen-related receptors (ERRs) (347, 348) as well as nonnuclear receptors, including forkhead box O1 (FOXO1) (349) and SREBP1 (346).
PGC1α and PGC1β serve diverse functions in multiple organ systems. PGC1α and
PGC1β are both highly expressed in mitochondria-enriched tissues with high energy
demands, including BAT, cardiac muscle/tissue, and slow-twitch skeletal muscle (342,
344, 345). However, PGC1α is enriched in the brain and kidneys. PGC1α is a coldinducible coactivator that is also stimulated in the skeletal muscle by exercise (350) and
in the heart and liver by fasting (351, 352). PCG1β is also induced by fasting, but not
cold exposure, indicating some conserved and some unique mechanisms of upstream
regulation of PGC1 proteins (344, 353).
PGC1α and PGC1β are the most robust coactivators of ERRα (342, 344, 345).
Under normal conditions, the PGC1/ERRα complex regulates metabolic homeostasis in
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tissues such as BAT and muscle. It is likely that some of the same mechanisms that
regulate PGC1/ERRα in normal physiology are also involved in cancer. For instance,
PGC1α is induced by hypoxia in the skeletal muscle, resulting in hypoxia-inducible factor
(HIF)-independent, but ERRα-dependent expression of VEGF and increased
angiogenesis (354). Additionally, the PGC1/ERRα complex is positively regulated by
oncogenic pathways in cancer cells. In breast cancer, HER2 activation increases the
expression of PGC1β (355) resulting in increased ERRα-dependent transcription (356).
As described in Chapter 3, PGC1β is a direct transcriptional target of Myc (260, 261),
which is overexpressed in a variety of cancers including colon cancer. We showed that
Myc expression is regulated by KSR1 in the colon tumor cell lines. Our lab has
previously published that PGC1α and PGC1β expression is independent of ERK1/2 in
mouse embryonic fibroblasts (187) and colon tumor cell lines (188), respectively, but is
dependent on the presence of activated Ras and KSR1 (187). With the recent
identification of a new MEK1/2 substrate, HSF1, I hypothesized that the KSR1dependent PGC1β expression in colon cancer cell lines is mediated by a MEK1/2dependent and ERK1/2-indpendent mechanism.

Results
Depletion of KSR1 reduces HSF1 expression
With the recent identification of HSF1 as a novel MEK1/2 substrate, we set out to
determine if KSR1 affected the phosphorylation of HSF1 at Ser326. We hypothesized
that KSR1 regulates HSF1 phosphorylation and possibly functions as a scaffold in a
proposed RAF/MEK/HSF1 cascade. To test whether KSR1 affects phosphorylation of
HSF1, KSR1 was depleted in HCT116 cells for 72 hours and protein levels were
assessed by western blot. KSR1 depletion reduced both phosphorylated and total levels
of HSF1 (Fig 4.1). The reduction in total HSF1 protein levels may be due to a decrease
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Fig 4.1 Depletion of KSR1 decreases pHSF1 (Ser326) and total HSF1 levels.
HCT116 cells were transfected with siRNA targeting KSR1 or a non-targeting siRNA
(Cont) for 72 hours. Protein expression levels were assessed by western blot.
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in HSF1 downstream targets, particularly heat shock proteins (e.g., HSP90) that stabilize
and sequester HSF1 in the cytoplasm. Additionally, depletion of KSR1 for 72 hours leads
to persistent MEK inhibition and prolonged MEK inhibition has been previously
demonstrated to reduce total HSF1 levels in malignant peripheral nerve sheath tumor
(MPNST) cells (357).

Prolonged Depletion of MEK1/2 decreases PGC1β expression
We have previously demonstrated that 24 hours of treatment with the MEK
inhibitors U0126 or PD0325901 does not decrease PGC1β expression in HCT116 cells
(188), but we never studied the effects of prolonged MEK1/2 inhibition on PGC1β. To
determine if PGC1β expression is dependent on the expression and activity of MEK1/2,
HCT116 cells were treated with DMSO or the MEK inhibitor U0126 for 0-96 hours. Due
to the short half-life of U0126 in medium, inhibitor was replenished every 24 hours. We
found that cells treated with U0126 had substantially decreased levels of PGC1β protein
by 24 hours (Fig 4.2). Levels of the co-activator ERRα protein were depleted in a similar
manner. PGC1β levels do decrease in DMSO-treated cells at the 72-hour and 96-hour
timepoints. At these timepoints, the wells are completely confluent, which may be
contributing to this decrease. However, at all timepoints, the expression of PGC1β is
less in MEKi-treated cells than in the controls (Fig 4.2). Previous studies suggest that
prolonged MEK inhibition can decrease KSR1 levels. Therefore, to rule out that the
effects on PGC1β were due to decreased KSR1 we assessed KSR1 expression at all
timepoints. Phosphorylation of ERK1/2 was used to assess the degree of MEK inhibition.
Next, we determined whether inhibition of MEK decreases PGC1β and ERRα
mRNA levels. As shown in Chapter 3, Myc regulates PGC1β expression in colon tumor
cell lines. Therefore, we also examined whether MEK inhibition decreased Myc mRNA
levels as well. HCT116 cells were treated with DMSO or 20 µM U0126 or PD98059 for
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Fig 4.2 MEK inhibition suppresses PGC1β and ERRα expression.
HCT116 cells were treated with 20 µM MEK inhibitor (U0126) or vehicle for 0-96 hours.
PGC1β and ERRα levels were assessed by western blot.
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48 hours. Treatment with the MEK inhibitors resulted in decreased Myc and PGC1β, but
not ERRα, mRNA levels (Fig 4.3A). It should be noted that although the decrease in
expression is small, 19-20% for Myc and 24-25% for PGC1β, it is statistically significant.
To verify that the inhibitors are working in this experiment, we treated a second set of
wells simultaneously for western blot analysis. Fig 4.3B shows that inhibition of MEK
decreases Myc, PGC1β, and ERRα protein expression in all replicates. It should be
noted that MEK1/2 inhibition decreases protein expression (Myc = 49%, PGC1β = 41%,
and ERRα = 51%) more than mRNA levels (Myc = 19%, PCG1β = 25%, and ERRα =
8% in U0126-treated cells. This suggests that MEK1/2 regulates these proteins via a
post-transcriptional mechanism.
siRNA-mediated depletion of MEK1/2 showed a significant decrease in mRNA
levels of Myc, but not PGC1β or ERRα (Fig 4.4). It is possible that using siRNA, the
effect on PGC1β takes longer to develop than it does using MEK inhibitors and would be
significant at later time points. Alternatively, this experiment may distinguish the ability of
kinase inhibition to more effectively debilitate MEK signaling than siRNA, which may not
be capable of targeting all MEK mRNA. Finally, these results may be indicative of offtarget effects of MEK kinase inhibitors.

MEK1/2 depletion inhibits Myc, PGC1β, and ERRα expression with and
without heat shock
To examine the contributions of MEK1 and MEK2 individually and elucidate the
mechanism behind MEK-dependent regulation of PGC1β, HCT116 cells were
transfected with siRNA targeting MEK1, MEK2, or MEK1/2 for 72 hours. Half of the cells
were subjected to heat shock (HS) at 43°C for 30 minutes to induce phosphorylation of
HSF1. Depletion of MEK1 or MEK2 alone did not have a significant effect on ERK1/2 or
HSF1 phosphorylation. However, simultaneous RNAi-mediated knockdown of MEK1/2
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Fig 4.3 MEK inhibition suppresses mRNA levels of Myc and PGC1β, but not ERRα.
(A) HCT116 cells were treated with 20 µM U0126 or PD98059 (or vehicle) for 48 hours.
Myc, PGC1β, and ERRα mRNA levels were measured by RT-qPCR. Data from three
biological replicates are presented as mean ± SD. Significance was measured using a
one-way ANOVA with a Dunnett’s multiple comparison post-test. * p < 0.05 (B) Duplicate
wells of each replicate in A were plated for western blot analysis of Myc, PGC1β, and
ERRα expression
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Fig 4.4 MEK depletion suppresses Myc mRNA levels.
MEK1 (MAP2K1) and MEK2 (MAP2K2) were simultaneously depleted in HCT116 for 72
hours. Myc, PGC1β, and ERRα mRNA levels were quantified using RT-qPCR. Data
from three biological replicates are presented as mean ± SD. Significance was
measured using a one-way, paired t-test. * p < 0.05
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decreased expression of activated ERK and HSF1 in the absence of HS (Fig 4.5).
Phosphorylation of HSF1 at Ser326 was stimulated by HS, even when MEK1/2 was
knocked down in the HCT116 cells, indicating that the residual activated MEK1/2 is
sufficient to phosphorylate HSF1 upon HS induction or that HSF1 may be
phosphorylated at Ser326 by an additional kinase in the colon tumor cell lines. Depletion
of MEK1 or MEK2 alone had minimal to no effect on Myc, PGC1β, or ERRα protein
levels. However, depletion of MEK1/2 together decreased levels of all three. It was
previously reported that sustained inhibition (96 hour) of MEK could decrease KSR1
levels (357). We, therefore, verified that the decreases observed in MYC, PGC1β, and
ERRα expression were not due to downregulation of KSR1.

MEK1/2 and ERK1/2 inhibition prevents HS-induced HSF1 phosphorylation
Previous reports suggest that the MEK-dependent HSF1 phosphorylation at
Ser326 is ERK-independent (335). Tang et al. treated HEK293T cells with 1 µM
FR180204 or 100 nM SCH772984 (two ERK1/2 inhibitors) overnight and measured
phosphorylated (Ser326) and total HSF1 by western blot (335). They found that
treatment with ERK inhibitors increased phosphorylation of Ser326 on HSF1 over that of
DMSO-treated cells. To confirm this finding in colon cancer cells, HCT116 cells were
treated with 20 µM U0126 or 1 µM SCH772984 for 24 hours. Surprisingly, inhibition of
MEK1/2 or ERK1/2 resulted in decreased levels of HSF1 phosphorylation (Fig 4.6). To
determine if inhibition of ERK1/2 also prevented HS-induced phosphorylation of HSF1,
HCT116 cells were subjected to 30 minutes of HS at 43°C after 24 hours of treatment
with U0126 or SCH772984. MEK1/2 or ERK1/2 inhibition was sufficient to block HSF1
phosphorylation following HS (Fig 4.6).

HSF1 inhibits the expression of Myc and PGC1β
HCT116 and Caco2 cells were transfected with MEK1/2 siRNA for 72 hours. To
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Fig 4.5 MEK siRNA decreases Myc, PGC1β, and ERRα expression.
HCT116 cells were transfected with siRNA targeting MEK1, MEK2, or MEK1/2 for 72
hours then subjected to the presence or absence of heat shock (HS) at 43°C for 30
minutes.
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Fig 4.6 Inhibition of MEK and ERK decreases pHSF1 (Ser326) expression in colon
cancer cells.
HCT116 and Caco2 cells were treated with 20 µM U0126, 1 µM SCH772984, or DMSO
for 24 hours then subjected to the presence or absence of heat shock (HS) at 43°C for
30 minutes. Protein expression levels were assessed by western blot.
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evaluate the nuclear translocation of HSF1, cells were harvested using
nuclear/cytoplasmic fractionation. Protein expression and compartmentalization was
assessed by western blot. In HCT116 and Caco2 cells, depletion of MEK1/2 reduced the
amount of phosphorylated HSF1 in the nuclear compartment (Fig 4.7). A similar pattern
is observed in Myc, PGC1β, and ERRα expression where reduced phosphorylated
HSF1 expression in the nucleus correlates with less Myc, PGC1β, and ERRα protein.
This suggests that nuclear translocation of HSF1 is necessary for sustained expression
of these transcriptional regulators.
To determine whether HSF1 directly promotes the expression of Myc, PGC1β,
and ERRα, HSF1 was knocked down by siRNA and protein expression was measured
by western blot. HSF1 depletion surprisingly increased Myc and PGC1β expression in
HCT116 and Caco2 cells (Fig 4.8). There was no effect on ERRα. Further, it was
determined that 72 hours of HSF1 depletion does not affect KSR1 levels or ERK
activation (Fig 4.8). Therefore, the increased Myc and PGC1β expression is not a
consequence of KSR1 or ERK1/2 signaling upregulation. These data suggest that
MEK1/2 regulates HSF1 phosphorylation and the expression of Myc and PGC1β through
independent pathways.

Activated ERK1/2 induces the expression of Myc, PGC1β, and ERRα
Inhibition of MEK1/2 through siRNA depletion and kinase inhibitors decreases
Myc, PGC1β, and ERRα expression via an HSF1-independent mechanism. Currently,
HSF1 and ERK1/2 are the only documented MEK1/2 substrates. We, therefore,
readdressed the possibility that MEK1/2 is regulating these proteins through an ERKdependent pathway. ERK1/2 was depleted in HCT116 and Caco2 cells for 72 hours by
siRNA and lysates were harvested using nuclear/cytoplasmic fractionation. In HCT116
and Caco2 cells, ERK1/2 depletion decreased Myc, PGC1β, and ERRα in the nucleus
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Fig 4.7 MEK depletion inhibits nuclear translocation of pHSF1 S326 in colon tumor
cell lines.
HCT116 cells were transfected with siRNA targeting MEK1/2 or control for 72 hours.
Nuclear and cytoplasmic fractions were isolated and protein expression levels were
assessed by western blot.
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Fig 4.8 HSF1 depletion increases Myc and PGC1β protein expression in colon
tumor cell lines.
HCT116 and Caco2 cells were transfected with siRNA targeting HSF1 or control for 72
hours. Protein expression levels were assessed by western blot.
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(Fig 4.9). Interestingly, 72 hours of ERK1/2 depletion increased total levels of
phosphorylated HSF1 (Ser326), 15% in HCT116 and 11% in Caco2, but did not affect
nuclear translocation (Fig 4.9). These data are consistent with the mechanism proposed
by Tang et al. (335), where ERK1/2 inhibition upregulates phospho-Ser326 HSF1
through inhibition or loss of a feedback loop and subsequent activation of MEK1/2.
A small-molecule inhibitor was used to assess whether ERK inhibition mimicked
the results from the knockdown studies. HCT116 and Caco2 cells were treated with 1
µM SCH772984 for 0-72 hours. Protein expression of Myc, PGC1β, and ERRα was
assessed by western blot. Inhibition of phospho-RSK was used as a positive control for
ERK inhibition. Treatment with SCH772984 decreased levels of Myc, PGC1β, and ERRα
in both cell lines by 24 hours (Fig 4.10). Taken together, these data suggest that the
expression of Myc, PGC1β, and ERRα are dependent on the activity of ERK1/2.

Discussion
Here we further define the mechanisms of Myc, PGC1β, and ERRα regulation in
colon tumor cells (summarized in Fig 4.11). We have identified that MEK1/2 plays a dual
role in the regulation of these proteins. Through the phosphorylation of HSF1, MEK1/2
inhibits Myc, PGC1β, and ERRα expression. However, as shown in Fig 4.3 and Fig 4.4,
this effect is overcome by the ERK-dependent promotion of Myc, PGC1β, and ERRα. In
the absence of HS, it is apparent that the MEK/ERK axis is the primary regulator of Myc,
PGC1β, and ERRα expression in colon cell lines. This may be due to ERK1/2dependent phosphorylation of HSF1 at Ser307, which antagonizes both nuclear
translocation and transcriptional activity of HSF1 in absence of stress (358). Fig 4.9
demonstrates that even with increased phosphorylation of HSF1 at Ser326 following
ERK1/2 siRNA-mediated depletion, Myc, PGC1β, and ERRα protein levels are still
decreased.
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Fig 4.9 ERK1/2 depletion inhibits Myc, PGC1β, and ERRα expression, but does not
affect nuclear translocation of pHSF1 S326 in colon tumor cell lines.
HCT116 and Caco2 cells were transfected with siRNA targeting ERK1/2 or control for 72
hours. Nuclear and cytoplasmic fractions were isolated and protein expression levels
were assessed by western blot.
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Fig 4.10 ERK inhibition decreases expression of Myc, PGC1β, and ERRα.
HCT116 (top) and Caco2 (bottom) cells were treated with 1 µM SCH772984 (ERK1/2
inhibitor) or vehicle for 0-72 hours. Myc, PGC1β, and ERRα levels were assessed by
western blot.
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Fig 4.11 Model of MEK/ERK-dependent regulation of Myc and PGC1β expression.
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The ability to induce HSF1 phosphorylation in the absence of MEK1/2 contradicts
data presented by Tang and colleagues (335). They showed that inhibition of MEK in
NIH-3T3 cells with 20 µM U0126 for 3 hours prior to HS (43°C x 30 minutes) was
sufficient to suppress phosphorylation of HSF1 at Ser326 (335). Interestingly, they also
show that HS induces phosphorylation of MEK and ERK in NIH-3T3 cells (335), which
we do not observe in the HCT116 cells. This suggests that the mechanisms regulating
MEK-dependent phosphorylation of HSF1 may be variable in different cell types.
Additionally, while Tang et al. (335) provide a plethora of circumstantial evidence
indicating MEK1/2 phosphorylates HSF1, they do not have a concrete experiment in
which purified, active MEK1/2 directly phosphorylates HSF1 at Ser326. This should be
addressed in future experiments.
Here we show that MEK1/2 and ERK1/2 inhibition for 24 hours can prevent HSinduced phosphorylation of HSF1 (Fig 4.6). However, after 72 hours of ERK1/2
depletion, HSF1 phosphorylation at Ser326 is increased. This is consistent with the idea
that MEK1/2 phosphorylates HSF1 at Ser326 and MEK1/2 activity is upregulated by
prolonged ERK inhibition via a negative feedback loop. The ERK1/2 activity is still
repressed at 72 hours as indicated by reduced RSK phosphorylation in Figures 4.9 and
4.10. The ability of ERK1/2 inhibition to prevent HSF1 phosphorylation at Ser326 at early
timepoints (24 hours), but to promote phosphorylation at late timepoints (72 hours) is
puzzling. It is possible that ERK1/2 directly phosphorylates Ser326, as the sequence
surrounding the phosphorylation site fits the consensus sequence for proline-directed
phosphorylation (359), but taking our studies and the previous studies by Tang et al.
(335) into account, this mechanism is unlikely. Alternatively, an ERK1/2-dependent
priming phosphorylation may be necessary for phosphorylation at Ser326. It is known
that sequential phosphorylation of Ser307 by ERK1/2 and Ser303 by GSK3β is
necessary for repression of HSF1 transcription (360) and FBW7-dependent
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ubiquitination (361). A similar priming phosphorylation may be required for subsequent
phosphorylation at Ser326. Finally, studies in HeLa cells indicate that mTOR complex 1
(mTORC1) can phosphorylate HSF1 at Ser326 (362). Cross-activation between the RasERK and PI3K-Akt pathways occurs when ERK1/2 phosphorylates RAPTOR to promote
Ras-dependent activation of mTORC1 (363). Therefore, ERK inhibition at 24 hours may
prevent the mTORC1-dependent phosphorylation of HSF1 at Ser326, but prolonged
ERK inhibition upregulates MEK1/2 through feedback loops and promotes MEK1/2dependent HSF1 phosphorylation. Mechanisms of ERK-dependent HSF1
phosphorylation need to be further defined.
The upregulation of Myc and PGC1β following depletion of HSF1 may be due to
HSF1-dependent promotion of HIF1α. In mammary cells, HSF1 regulates HIF1α
translation via upregulation of HuR, which generally promotes mRNA stability and
translation (364). HuR is overexpressed in a variety of cancers and correlates with
cancer progression, including colon cancer progression (365-368). HIF1 regulates Myc
by two mechanisms: 1) HIF1 binds to and activates transcription of MXI1, which encodes
a repressor of Myc transcriptional activity, and 2) HIF1 promotes MXI1-independent,
proteasome-dependent degradation of Myc (261). Alternatively, HuR has been shown to
directly bind to Myc mRNA and decrease its expression (369). Further work needs to be
conducted to determine if either of these mechanisms are relevant in colon tumor cell
lines.
Here we present the novel finding that MEK1/2 promotes PGC1β and ERRα via
an ERK-dependent mechanism (Fig 4.2 and Fig 4.3). This conclusion is supported by
both direct depletion of ERK1/2 using siRNA and small-molecule inhibition experiments
(Fig 4.9 and Fig 4.10). As demonstrated here, the two MEK1/2 substrates may have
opposing roles on common downstream targets, such as HSF1-dependent inhibition and
ERK1/2-dependent promotion of Myc and PGC1β expression (Fig 4.8 and Fig 4.9). With
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the identification of an additional MEK1/2 substrate, HSF1, moving forward it will be
essential to distinguish between MEK1/2- and ERK1/2-dependent mechanisms.
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Chapter 5: Conclusions
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The experiments in this dissertation sought to identify additional vulnerabilities in
cancer cells that, like KSR1 depletion, may be targets for cancer therapeutics and further
define the molecular mechanisms that regulate key proteins in colon cancer survival. In
the course of these studies, we identified several mechanisms by which cells regulate
Myc and PGC1β expression in human CRC. We demonstrate that depletion of KSR1 or
EPHB4 negatively regulates the protein levels, whereas depletion of HSF1 actually
increases Myc and PGC1β protein expression. We further show that KSR1 and EPHB4
decrease Myc expression via different mechanisms. KSR1 depletion does not affect Myc
and PGC1β mRNA expression, whereas depletion of EPHB4 decreases mRNA levels of
both. In support of separate mechanisms of Myc and PGC1β regulation, the effects of
KSR1 on Myc and PGC1β protein levels are ERK-dependent. However, EPHB4
depletion does not affect MEK or ERK phosphorylation in these cell lines. The data
presented here expand our understanding of mechanisms that regulate Myc and PGC1β
expression and highlight vulnerabilities in colon tumor cells that may be exploited using
targeted therapies.

Is KSR1- or EPHB4-mediated expression of Myc and PGC1β
dependent on activation of the RAS/RAF/MEK pathway?
The results reported here are consistent between HCT116 and Caco2 cells.
HCT116 cells are heterozygous for K-RasG13D, while Caco2 cells are K-RasWT.
Importantly, Caco2 cells express moderate levels of EGFR (370) and respond initially to
anti-EGFR therapies with decreased proliferation (371) before acquiring MET/Srcdependent resistance (372). Signaling via c-MET can activate Ras and promote Rasdependent signaling in the presence of EGFR inhibition (373). Therefore, Caco2 cells
may depend on Ras-dependent signaling for survival even in the absence of mutated
and constitutively activated Ras.
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In addition to Ras activation, defects in the APC pathway occur in 80-90% of
human colon carcinomas, resulting in enhanced TCF-dependent transcriptional
activation of Myc and EPHB4 (271, 273). Cells with APC mutations lose the ability to
regulate β-catenin signaling. Alternatively, cells can acquire a mutation in CTNNB1
(gene encoding β-catenin). These mutations activate β-catenin-dependent signaling by
decreasing their negative regulation (374). Both HCT116 and Caco2 cells harbor
mutations in β-catenin leading to constitutive activation. HCT116 cells have WT APC
and heterozygous β-cateninΔSer45 (374). The Ser45 residue is phosphorylated by CK1α
as a priming site for GSK3β-dependent phosphorylation at Thr41, Ser37, and Ser33 and
subsequent degradation by E3 ubiquitin ligases (375). Therefore, β-catenin protein in
HCT116 cells is resistant to GSK3β-dependent regulation. β-catenin with the Ser45
residue deleted acts as a dominant negative, increasing β-catenin/TCF-mediated
transcriptional activity (374). Caco2 cells are an example of cells that have mutant forms
of both APC and β-catenin. However, the mutation in β-catenin is different than that
found in HCT116 cells. Caco2 cells have a heterozygous G to C missense transversion
that results in a glycine to alanine mutation at residue 245 (374). This mutation is directly
N-terminal to a serine residue that is phosphorylated by CDK5 (376). Therefore, it is
predicted that the G245A mutation increases the accessibility of Ser246 for
phosphorylation and β-catenin activation. These mutations in β-catenin may be a
mechanism by which HCT116 and Caco2 cells upregulate EPHB4 expression.
Recent work has identified pathway cross-talk in which activated K-Ras4B
promotes tumorigenicity by inhibiting non-canonical Wnt/Ca2+-signaling in pancreatic
cells (377). The non-canonical Wnt/Ca2+ pathway involves activation of calmodulin
(CaM) kinase II (CaMKII) and the transcription factor NF-AT as well as the inhibition of βcatenin/TCF signaling by blocking the interaction between β-catenin and TCF4. KRas4B,
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but not H-Ras, N-Ras, or K-Ras4A, binds to and sequesters CaM, thereby preventing
CaMKII activation. In colon tumor cells lines, knockdown of K-Ras significantly represses
β-catenin/TCF/LEF transcriptional activity and proliferation in SW480 (mutant for APC,
wild-type β-catenin), but not HCT15 (mutant APC) or HCT116 (wild-type APC) cells with
activating β-catenin mutations (377). However, Wnt/Ca2+/CaMKII-dependent signaling
also inhibits sphere formation in 3D culture. Inhibition of Ras downregulates CaMKII
activity and prevented sphere formation in the three cell lines (377). Therefore, even in
the presence of activated β-catenin, activated Ras can regulate the non-canonical Wnt
signaling pathway to modulate tumorigenesis.
In the present study, we did not directly examine the effects of KSR1 or EPHB4
depletion on canonical or non-canonical Wnt/β-catenin signaling. However, when we
observed that KSR1 depletion decreased EPHB4 protein levels, we did test whether this
effect was due to regulation of mRNA levels or protein stability. We show that KSR1
depletion does not affect EPHB4 mRNA expression (Fig 3.21) suggesting that KSR1 is
not regulating the Wnt/β-catenin-dependent transcriptional activation of EPHB4.
Additionally, Wnt/β-catenin-signaling induces transcription of Myc. Taken together, it is
unlikely that KSR1 is acting through Wnt/β-catenin canonical signaling to promote the
upregulation of Myc and EPHB4 expression.
The mechanisms by which KSR1 and EPHB4 regulate Myc and PGC1β
expression in colon tumor cell lines need to be further defined. Previous work
demonstrates that inhibition of EPHB4 using a monoclonal antibody reduces proliferation
and increases apoptosis in HT-29 (K-RasWT, B-RAFV600E) xenografts (378). Together with
our studies showing that EPHB4 depletion is toxic to colon tumor cell lines harboring
mutant and wild-type K-Ras in the absence of activated B-RAF, these data suggest that
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EPHB4 inhibition may be a viable therapeutic strategy selectively targeting colon tumor
cells regardless of mutations in the Ras/RAF/MEK signaling pathway.

Regulation of Myc in colon tumor cell lines
Dysregulation of Myc occurs in more than half of all human tumors and often
correlates with aggressive disease (264, 265), resistance to therapy (266-268), and poor
prognosis (269-271). Myc activates or represses the transcription of a large number of
genes involved in key cellular processes such as cell growth, metabolism, apoptosis,
and protein synthesis (272). The Cancer Genome Atlas (TCGA) Network found that, in a
comprehensive examination of human colon and rectal cancers of diverse anatomical
origin and mutation status, changes in Myc transcriptional targets were found in nearly
100% of the tumors (280), suggesting an important role for Myc in CRC. Therefore,
finding novel ways to target Myc may clinically benefit patients with colorectal cancer.
Ras activation and subsequent phosphorylation events enhance Myc protein
stability (277, 278). ERK1/2-, CDK-, or JNK1/2-dependent phosphorylation of Ser62
stabilizes Myc expression, but also primes Myc for GSK3β-dependent phosphorylation at
Thr58. Following phosphorylation at Thr58, Ser62 is dephosphorylated by PP2A and
ubiquitinated for proteasome-mediated degradation by SCFFBW7 E3 ligase (277, 278). In
the absence of the stabilizing phosphorylation at Ser62, Myc is rapidly degraded by
alternative mechanisms (277). Here we show that while depletion of KSR1 and EPHB4
decrease phosphorylation of Myc at Ser62 (Fig 3.14); however, inhibition of
phosphorylation is incomplete and Myc protein stability is unaffected by the absence of
KSR1 or EPHB4 (Fig 3.16).
Protein synthesis is promoted by mTORC1 and the downstream S6K due to their
ability to phosphorylate and thereby inactivate 4E-BP1 and PDCD4 proteins, which
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inhibit the translation initiation complex (379, 380). As a consequence, inhibition of
mTORC1 blocks Myc expression in myeloma cells, and targeting protein translation with
silvestrol limits the growth of Myc-driven hematopoietic tumors (381). However,
treatment with a dual mTOR/PI3K inhibitor (BEZ235) failed to suppress the translation of
Myc, and often times enhanced Myc expression, in colon tumor cell lines (382).
Furthermore, treatment with BEZ235 enhanced phosphorylation of ERK1/2 in K-Ras
wild-type and K-Ras mutant colorectal cancer lines (382). The ERK1/2 substrate RSK
also phosphorylates 4E-BP1 and PDCD4 to promote protein translation (304, 383). Due
to the role of KSR1 as a scaffold of the RAF/MEK/ERK kinase cascade, we predict that
the KSR1-depedent promotion of Myc translation is due activation of RSK.
Myc translation can be initiated via a cap-dependent and -independent (IRESdependent) mechanisms (230, 306). Our data suggest that KSR1 can promote both
mechanisms of Myc protein synthesis (Fig 3.18 and 3.19). However, depletion of KSR1
also suppresses the phosphorylation of 4E-BP1 and PDCD4, key inhibitors of global
translation. The idea that KSR1 affects global protein synthesis should be addressed in
future studies. Tumors can develop an enhanced ability to promote cap-dependent
protein synthesis by overexpressing eIF4E or loss of 4E-BP, [reviewed in (384)].
However, during apoptosis, growth arrest, mitosis, hypoxia, or amino acid starvation,
cap-dependent translation is suppressed and IRES-mediated translation is induced (307,
385). In addition to Myc, IRES-dependent translation of mRNAs encoding HIF1α,
VEGFA, Bcl2, X-linked inhibitor of apoptosis (XIAP), and p120Catenin has been
reported [reviewed in (384)]. It is important to note that we have only tested the ability of
KSR1 to promote IRES-mediated translation of Myc. However, if KSR1 promotes global
IRES-mediated translation, there may be a KSR1-dependent mechanism by which
cancer cells survive during times of stress.
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The action of HSF1 is multifaceted. It promotes cell proliferation and survival in
response to diverse oncogenic stimuli, enhances ERK activation in response to serum
starvation, modulates protein translation, and supports glucose uptake and glycolysis
(333). While HSF1 is not necessary for survival in normal conditions, it is required during
the heat shock response and the proteotoxic stress induced by oncogenesis (357). Due
to the role of HSF1 in proteostasis and heat shock response, it was anticipated that
upregulation of Myc and PGC1β by HSF1 would promote survival in the presence of
stress. In contrast to EPHB4 and KSR1, the presence of HSF1 actually decreases the
expression of Myc and PGC1β protein (Fig 4.8).
Recent reports demonstrate that HSF1 plays an essential role in the
development of lymphomas in p53-deficient mice and the development of carcinomas in
a Ras tumor model (333, 386). This role in early-stage tumorigenesis is likely due to a
role for HSF1 in evasion of oncogene-induced senescence (387). Tumor maintenance is
also dependent on HSF1-mediated expression of HuR, which can stabilize and promote
HIF1α translation (387). Upregulation of HuR controls mRNA stability and/or translation
of many proteins involved in cancer, including proteins involved in angiogenesis (e.g.,
HIF-1, HIF-2, and vascular endothelial growth factor [VEGF]), cell survival (e.g., p53 and
Sirt1), proliferation (e.g., cyclins, Cdc2, and p21), and others (365, 368). The HuRdependent reduction in Myc mRNA expression (364) or stability (369) may be overcome
by the ERK-dependent promotion of protein stability or translation in CRC cells.

Regulation of PGC1β in colon tumor cell lines
We demonstrate here that the expression of PGC1β is regulated by a variety of
mechanisms including KSR1- and EPHB4-dependent upregulation and HSF1-dependent
suppression. However, with the exception of the induction of apoptosis, we do not
examine the downstream effects of PGC1β depletion in colon tumor cells. PGC1s are a
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small family of transcriptional coactivators that augment the responses of transcription
factors and play a critical role in the control of metabolism (388). PGC1 coactivators
directly interact with nuclear receptors, including PPARα and PPARγ, estrogen-related
receptors (ERRs), liver X receptors (LXR), hepatocyte nuclear factor 4α (HNF-4α), and
non-receptor transcription factors and regulatory elements including cAMP response
element-binding protein (CREB), the lipogenic transcription factor sterol regulatory
element binding protein 1c (SREBP-1c), and forkhead box O1 (FOXO1) (388).
Therefore, further examination of PGC1β-mediated signaling in both normal and tumor
cells is warranted.
Lipogenic nuclear receptors LXRα and LXRβ are nutrient-responsive receptors
that heterodimerize with RXR to influence gene expression promoting fatty acid (FA)
biosynthesis and triacylglycerol (TAG) secretion (388). LXR increases the synthesis of
FA and TAG by upregulating sterol regulatory element binding protein 1c (SREBP-1c)
(389). PGC1β plays a critical role in stimulating the expression of genes that regulate
hepatic lipogenesis and TAG secretion (388). Adenoviral-mediated overexpression of
hepatic PGC1β in rats induces increased TAG synthesis and VLDL secretion leading to
hypertriglyceridemia and hypercholesterolemia (347). PGC1β induces lipogenesis in the
liver by coactivating both LXR and SREBP-1 to promote expression of FA synthase
(FAS), stearoyl-CoA desaturase (SCD1), and HMG-CoA reductase (HMGCR) (347).
Both PGC1β and SREBP-1c, but not PGC1α, are induced in the liver in response to an
acute high fat diet (24-48 h) (347).
Previous work in our lab shows that KSR1 regulates adipogenesis by
coordinating ERK- and RSK-dependent phosphorylation and stabilization of
CCAAT/enhancer-binding protein beta (C/EBPβ) (186). C/EBPα, C/EBPδ, and C/EBPβ
transcription factors promote PPARγ expression (390). C/EBP transcription factors also
regulate SREBP-1c gene expression during adipogenesis (391). Therefore, KSR1 may
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contribute to lipid accumulation by both promoting the expression of nuclear receptors as
well as stabilizing the co-activator PGC1β.
PGC1β induces angiogenesis in skeletal muscle (392). Angiogenesis can occur
under pathological conditions, such as tumor growth, and physiological conditions, such
as embryonic development and exercise. It is triggered by the secretion of soluble
factors, including VEGF, PDGF, angiopoietin (ANGPT), and FGF, from tissue (393).
Under hypoxic conditions, hypoxia-inducible factor 1α (HIF-1α) is stabilized and free to
dimerize with HIF-1β to activate proangiogenic genes such as VEGF (394). However,
PGC1β induces the expression of VEGF in cell culture and in vivo via an ERRαdependent and HIF-1α-independent mechanism. EPHB4 signaling is a potent regulator
of VEGF-dependent angiogenesis (395-398). Several studies observed that EPHB4ephrinB2 reverse signaling regulates VEGF-dependent pathways by specifically
preventing VEGFR internalization required for activation of such pathways (396, 397).
Alternatively, others have reported that EPHB4-ephrinB2 forward signaling is required
for angiogenesis, as a small molecule inhibitor of EPHB4 kinase activity suppresses
VEGF-driven angiogenesis in vivo (398). Future work should address whether EPHB4
forward signaling-dependent potentiation of angiogenesis is due to its ability to promote
PGC1β expression.
We show that inhibition of Myc suppresses PGC1β mRNA expression in colon
tumor cell lines (Fig 3.8). However, additional experiments indicate that in the presence
of cycloheximide, PGC1β protein expression can be rescued by the addition of MG132
for 2 hours (McCall, data not shown). This suggests that PGC1β expression is not
entirely dependent on the transcriptional regulation by Myc. PGC1 proteins are modified
by post-transcriptional modifications, primarily reversible acetylation, phosphorylation,
and methylation (388). Both PGC1α and PGC1β complex with the acetyltransferase
GCN5 (general control of amino acid synthesis 5); GCN5 then acetylates several lysine
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residues on PGC1 proteins to inhibit their transcriptional activity (399, 400). This is
opposed by SIRT1 (sirtuin 2 ortholog 1)-dependent deacetylation and activation (400,
401). Interactions between KSR proteins and SIRT1 have been identified (Fernandez
and Lewis, unpublished), but KSR1-dependent acetylation of PGC1 proteins has not
been examined thus far.
Phosphorylation of PGC1β is relatively unstudied. Dr. McDonnell’s group at Duke
University has identified several serines on PGC1β that are predicted to be
phosphorylated, and they modified those serines to alanines to inhibit phosphorylation
(personal communication). We examined the expression of four of these constructs
(S256A, S384A, S524A, and S638A) with and without the addition of the proteasomal
inhibitor, MG132. Interestingly, PGC1βS638A had the lowest expression without MG132,
but relatively equal expression as the other constructs in the presence of MG132 (Das
and Lewis, unpublished). Further examination of this site indicates that there is a proline
at the +1 position (LSLPsPEGLSLK). Therefore, the potential that ERK1/2, or
alternatively MEK1/2, phosphorylates PGC1β at this site should be examined. The lysine
at 645 is the equivalent of the GCN5-dependent acetylation site on PGC1 proteins in
mice (400). The relationship, if present, between Ser638 phosphorylation and K645
acetylation should be examined. Furthermore, we have previously published that PGC1β
is ubiquitinated in colon tumor cell lines (188). Therefore, determining the residue(s)
modified by ubiquitination would be beneficial in further defining the mechanisms
regulating PGC1β protein expression.

Summary
Cells are regulated by a vast network of signaling pathways that maintain cell
homeostasis. Alterations in these networks can lead to the promotion of tumor
development. The studies described here identify vulnerabilities in colon tumor cells that
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can be exploited for therapeutic intervention. Currently, there are several inhibitors of
EPHB4 signaling, including monoclonal antibodies and kinase inhibitors that are being
developed as cancer therapeutics. But thus far targeting KSR1 directly has been elusive.
However, depletion of EPHB4 or KSR1 in colon tumor cell lines results in the decreased
expression of common effectors, Myc and PGC1β. The results of these experiments
further demonstrate that Myc and PGC1β expression are regulated by multiple
mechanisms in colon tumor cells. The data show that depletion of KSR1 or EPHB4
decreases Myc and PGC1β levels, while depletion of HSF1 increases their expression.
While previous work demonstrated ERK-dependent regulation of Myc stability, these
data are the first to show that KSR1-dependent regulation of PGC1β is mediated by ERK
activation. Therefore, in addition to EPHB4 inhibitors, the use of ERK inhibitors may
prove to be a viable option for the treatment of patients with colon tumors.
In future studies, it will be important to determine if Myc-dependent expression of
PGC1β enhances the oxidative and glycolytic capacity of the colon tumor cells. If so, the
extent to which this mechanism is common among tumor types that demonstrate
elevated levels of protein translation should be assessed. Furthermore, it should be
determined whether the Myc-mediated increase in PGC1-dependent metabolic capacity
is restricted to cells with increased translation of Myc mRNA or if it is also present in
cells with increased Myc expression due to alternative mechanisms (e.g. gene
amplification). Finally, the extent to which this mechanism represents a unique
vulnerability to tumor cells should be examined.
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Appendix A: Characterizing the roles of KSR1 and KSR2
in mouse behavior and lessons on littermate controls
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Rationale
Anxiety (including panic disorder, generalized anxiety disorder, and social
phobia) is a common non-motor symptom in 25-49% of patients with Parkinson’s
disease (PD) (402, 403), a rate higher than that reported in healthy or comparably
disabled elderly controls, indicating that anxiety is associated with the disease
mechanism rather than purely social distress due to motor impairment. Anxiety is
considered a normal adaptive response that detects and prepares an individual against
an imminent or potential threat; however, increased anxiety has a negative impact on
health-related quality of life (404).
The physical symptoms of PD mainly result from progressive and profound loss
of dopaminergic neurons that project to the striatum, but are also associated with losses
in the pathways that project to the amygdala and hippocampus (405). The amygdala is
considered the key structure responsible for the generation of emotional behaviors (406)
including fear-related behaviors (407, 408). In fact, levels of dopamine (DA) in the
amygdala are increased in response to aversive events (409). Furthermore, DA
signaling in the amygdala and striatum are required for learning and maintaining
conditioned avoidance responses (410).
Anecdotal observations from Lewis lab members suggested that mice lacking
ksr2 are abnormally calm when handled. Previous work in other labs has demonstrated
that ksr1 is required for some forms of long-term associative memory formation (411).
KSR proteins are highly expressed in the brain (411, 412), including in the hippocampus
and the amygdala (411), but little is known about their functions. KSR1 is expressed in
both the cell bodies and dendrites of the neurons in the CA3 region of the hippocampus,
but not glial cells (411). KSR2 is also expressed in the hippocampal neurons (Guo &
Lewis, unpublished). However, brains of ksr knockout mice do not show any gross
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alterations in brain morphology compared to wild-type mice (411) (Costanzo-Garvey &
Lewis, unpublished). It has been reported that in the hippocampus, KSR1 is important
for protein kinase C (PKC)-dependent ERK signaling, but does not mediate the cyclic
AMP (cAMP)/protein kinase A (PKA)-dependent pathway (411). KSR1 is also important
for long-term associative memory formation (411) and both PKA and MAPK/ERK
signaling are required for long-term potentiation (LTP) in the hippocampus (413-415)
and amygdala (416). Due to the high level of KSR1 expression in the amygdala, we
sought to determine whether KSR proteins functioned in the brain to regulate anxietyand depression-related behaviors.

Methods
Open Field
Mice are placed in a 49 cm x 49 cm x 38 cm white box and allowed to explore for 20
minutes. Locomotor paths are monitored using a video tracking system, Ethovision
(Noldus, Leesburg, VA, USA), and analyzed for time in the center (defined as 7 cm from
each wall), total distance traveled, as well as total distance traveled in the center. This
test measures both anxiety (increased time spent in the center) and habituation
(persistent exploration).

Elevated Zero
A zero maze (34 cm ID and 46 cm OD, braced on 4 legs, 40 cm tall) is used according to
procedures previously described (417). Briefly, mice are placed in the center of one of
the closed quadrants and are allowed to move freely in the maze for 6 minutes. Latency
to enter an open quadrant, time spent in open quadrants, and number of zone transitions
(all four paws transferring from the open arm to closed arm or vice versa) are scored by
two blinded observers. The elevated zero maze complements the open field test, but is a
better measure of pure anxiety (418). Mice are naturally exploratory, but tend to avoid
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open and potentially dangerous areas [reviewed in (418)]. Therefore, mice prefer to
remain in the closed arms of the maze. Mice who venture out more often (quantified as
zone transitions) and spend more time in the open arms are classified as anxiolytic.

Forced Swim Test (FST)
A 1 L beaker is filled halfway with warm water. The test mouse is then placed into the
beaker. The water is deep enough that the animal has to either swim or float to remain
above the surface (it cannot stand), but the walls are too high to permit escape. The trial
is videotaped for 6 minutes. At the end of this period, the mouse is removed from the
beaker, dried with a paper towel, and returned to its home cage. The beaker is emptied
and refilled in preparation for testing the next mouse. Primary outcome is the amount of
time actively resisting (either swimming or attempting to climb) compared to the amount
of time spent floating. Antidepressant phenotypes are characterized by greater amounts
of time floating rather than swimming/climbing.

Tail Suspension
A thin aluminum rod (the crossbar) is mounted using standard clamps across two lab
stands that are parallel to the table surface, and approximately 0.3 m above the surface.
The mouse is removed from the home cage, and is gently fastened to this crossbar
using adhesive masking tape. The mouse is then videotaped for 6 minutes. At the end
of this period, the mouse is removed from the bar, the tape removed from the tail, and
the animal returned to its home cage. The bar and adjoining areas are cleaned with
chlorohexidine in preparation for testing the next mouse. Primary outcome is the
amount of time spent actively resisting this position compared to the amount of time
dangling without any visible muscular exertion. Antidepressant phenotypes are
characterized by greater amounts of time dangling rather than resisting.
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Stereotypy
The open field arena was “binned” into nine regions that varied in size, but
contained similar numbers of data points per bin. The bins were constrained in that they
were set as rectangles that shared a common row, but not column. Raw locomotor (x,y)
coordinate data from the video tracking system were imported into MATLAB (MathWorks
Inc, Natick, MA, USA). Data were binned using a MATLAB algorithm provided by Dr.
Bonasera, as previously described (419). Patterns were required to be longer than two
bins and not overlap in time to proceed with analyses. A commercially available program
(Theme, Noldus) was used to evaluate pattern structure. Within a given trial, we
calculated what percentage of total trial time the animal is engaged in route-tracing
behavior. We also determined the maximum length of patterns from each trial.

Statistics
All statistics were performed using Prism Software (GraphPad). All data are
presented as mean ± SEM. Data presented as genotypes over time were analyzed with
a two-way ANOVA with Bonferoni’s post-test for multiple comparisons. Figures with two
columns were analyzed using a two-tailed, student’s t-test. All others were analyzed with
a one-way ANOVA with Bonferoni’s post-test for multiple comparisons. A p value of less
than 0.05 was considered statistically significant.

Results and Discussion
Pilot study with non-littermate WT controls indicates that KSR1 is
important in mouse anxiety
Age-matched ksr1-/- male mice (5-6 weeks in age) were placed in an open field
arena (one at a time) and allowed to freely roam for 20 minutes. This test measures
anxiety, exploration, and habituation behaviors. Sessions were recorded with an
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overhead camera and route mapping was performed using Ethovision software. A wildtype mouse will typically spend time in the corners and around the edges of the arena,
displaying thigmotactic behaviors.	
  A mouse that enters the center of the arena more
often is considered anxiolytic or less anxious.
Examples of wild-type and ksr1-/- mice route maps are shown in Fig A.1A. In the
open field test, ksr1-/- mice travel further (Fig A.1B) and spend significantly more time in
the center than the wild-type controls (Fig A.1C). Since ksr1-/- mice exhibit increased
locomotive activity as compared to WT controls, we quantified the stereotypic behaviors
(specifically route-tracing) displayed by each phenotype. Stereotypies are defined as
motor actions of unknown functional purpose that are repeatedly performed in a nearidentical manner (420, 421). These behaviors may include patterns (route-tracing),
repetitive head movements, and syntactic grooming (420). Increased stereotypic
behaviors are a behavioral correlate of aberrant striatal function (422-424). Particularly,
increased DA receptor stimulation at synapses within the striatum can induce increases
in stereotypy (419, 425). To quantify the patterns of routes taken by each mouse, we
used t-pattern sequential analyses (419, 426). This is a mathematical approach that
determines whether a sequence of events occurs within a specified time interval at a
rate greater than that expected by chance. ksr1-/- mice spend a larger percentage of their
time performing stereotypic behaviors (Fig A.1C), but do not have longer patterns than
their wild-type counterparts (Fig A.1D).
To determine if this anxiolytic phenotype is also observed in the elevated zero
maze, ksr1-/- and wild-type mice were placed in the closed arm of the elevated zero
maze and allowed to freely explore for six minutes. In this test, mice are given a choice
to spend time in the unprotected, open arm, or the protected, closed arm. Mice generally
avoid open areas, especially when brightly lit. Therefore, while it is common for a wildtype mouse to transition to the other closed arm, they usually run quickly to get out of the
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Fig A.1 Age-matched ksr1-/- mice display an anxiolytic phenotype as measured in
the open field arena.
Age-matched WT and ksr1-/- mice (5-6 weeks, male) were tested using the open field
test. (A) Example of data analyzed for each genotype. (B) Cumulative distance traveled.
(C) Cumulative time spent in the center of the arena. (D) Percentage of time spent in
stereotypic (repetitive) patterns. (E) Average length in longest pattern.
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open space. Again, all trials were recorded using an overhead video camera system and
route-mapping for each trial was performed using Ethovision software (Noldus).
An example of the arena and maps for each genotype are shown in Figure A.2A.
ksr1-/- mice exhibited an abnormal locomotive pattern during the elevated zero maze (Fig
A.2C). They also spend significantly more time in the open arm of the elevated zero
maze than wild-type mice (Fig A.2D). Taken together, these data suggest that ksr1-/mice have decreased anxiety.
Age-matched ksr1-/- female mice (5-6 weeks of age) also exhibit a significant
anxiolytic phenotype in the elevated zero maze, but fail to recapitulate the phenotype
seen in the male mice in the open field test (data not shown).

Age-matched ksr2-/- mice trend towards decreased anxiolytic phenotypes
Given our anecdotal evidence that ksr2-/- mice appear to be calmer when
handled than wild-type mice, we tested the effect of genotype on anxiety-related mouse
correlates using the open field arena and elevated zero maze. Male and female ksr2-/and wild-type mice were tested. Only male data are presented here. ksr2-/- mice have
slightly more total movement in the open field than wild-type mice (Fig A.3A). They also
spend slightly more time in the center (Fig A.3B). However, the route-tracing stereotypic
phenotypes observed in mice lacking ksr1 are not present in ksr2-/- mice (Fig A.3C-D).
We further tested these mice in the elevated zero maze. Again, ksr2-/- male mice have a
trend of increased locomotion (Fig A.3E) and increased time spent in the open arms of
the elevated zero maze (Fig A.3F), but these results are not significant. ksr2-/- female
mice did not exhibit these trends.
Taken together, male mice lacking ksr2 have a trend towards anxiolytic
phenotypes, but the results were not significant for the open field and elevated zero
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Fig A.2 Age-matched ksr1-/- mice display an anxiolytic phenotype as measured in
the elevated zero maze.
Age-matched WT and ksr1-/- mice (5-6 weeks, male) were tested using the elevated zero
maze. (A) Example of data analyzed for each genotype. (B) Cumulative distance
traveled. (C) Cumulative time spent in each arm of the maze.
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Fig A.3 Age-matched ksr2-/- mice do not display anxiolytic phenotypes.
Age-matched WT and ksr2-/- mice (5-6 weeks, male) were tested using the open field
test (A-D) and the elevated zero maze (E-F).
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maze. However, power calculations indicate that significance may be obtained using
additional mice (12 and 7 for open field and elevated zero maze, respectively).

Littermate-controlled studies indicate that KSR1 does not affect mouse
anxiety
Several confounding factors can affect the results of behavioral tests (427-429).
Therefore, it is recommended that all studies are performed with littermates. Additionally,
the estrus cycle can affect results; so male mice are preferentially used in these assays
(430). To address these issues, we repeated the assays using a littermate-controlled
cohort of wild-type, ksr1+/-, and ksr1-/- male mice (5-6 weeks in age). This group failed to
recapitulate any of the original phenotype observed in the pilot study (Fig A.4). This may
be due to several reasons: 1) the pilot study used age-matched controls, whereas the
current study used littermate controls; 2) the pilot and current studies were performed in
different seasons, which may affect mouse behaviors. The first point is very important
because maternal behavior during the neonatal period has been shown to regulate
anxiety in adult mice (431); therefore, it is essential to use matching littermate, wild-type
controls in these analyses.
Interestingly, data from age-matched and littermate-matched ksr1-/- mice are
nearly identical in all reported measurements. However, the wild-type mice are
significantly different. Of major note is that in the pilot study, these genotypes not only
came from different litters, but were also derived from parents with different genotypes.
The ksr1-/- mice are fertile and at the time of the study the colony was maintained using
null x null crosses. The wild-type mice were obtained from wild-type x wild-type crosses
or from the ksr2 colony. ksr2-/- mice are infertile and their colony is maintained ksr2+/- X
ksr2+/- breeding. Additionally, ksr2-/- mice often do not survive until weaning. In pilot
studies, we used the “extra,” age-matched wild-type mice from the ksr2+/- X ksr2+/- cross
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Fig A.4 Littermate-controlled ksr1-/- mice do not display anxiolytic phenotypes.
Age-matched WT, ksr1+/-, and ksr1-/- mice (5-6 weeks, male) were tested using the open
field test (A-D) and the elevated zero maze (E-F).
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to pair for comparison to ksr1-/- mice.
Furthermore, each colony is numbered differently for genotyping in the second
week of life. Mice in the ksr1 colony and wild-type crosses are healthy and large. They
are marked using ear clipping. Knockout mice in the ksr2 colony are weak and very
small. We have an issue with ear clippings tearing and generally being too large for their
ear size. Therefore, we have an exemption from IACUC to mark these mice using toe
clippings. Recent studies indicate that toe clipping does not adversely affect the behavior
studies we performed. Thus, it is anticipated that the clipping method is not the primary
cause for the significant differences observed in the wild-type groups (432, 433).
It is likely that maternal care is drastically different in these three breeding
schemes and may be contributing to the differences we observed in the wild-type mice.
Animal studies support the idea that physical and emotional neglect and parental loss
during childhood can lead to negative consequences in adulthood, such as an increased
likelihood to develop depression and anxiety disorders (434, 435). In rats, males that
undergo maternal separation (MS) for 3-4.5 hours a day for the first 2 or 3 weeks of life
exhibit an increase in fearfulness in adulthood (436, 437). Males that undergo repeated
separation show greater hypothalamic-pituitary-adrenal activity both basally and in
response to an acute stressor upon reaching adulthood (437, 438). In C57BL/6 mice,
behaviors of males and females can be altered by MS (431). Specifically, they show that
maternally separated males showed higher levels of anxiety and fear behavior in
adulthood, as measured by the open field test and elevated plus maze, compared to
control males. Conversely, they found that maternally separated females exhibit less
anxiety and fear behavior in adulthood, but only during diestrus (431), suggesting that
estrus cycle should be monitored when conducting behavioral studies. Thus, it appears
that early life stressors in the form of maternal separation can have a lasting influence on
the physiology and behavior of offspring for both rats and mice.
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Future work addressing the differences in maternal care among the colonies
would be relevant to this work, but was not pursued. However, this work did shift the way
the breeding colonies are managed. We now breed ksr1-/- mice from ksr1+/- X ksr1+/crosses for all studies. Furthermore, we have started producing inducible ksr2fl/fl mice.
Under the traditional breeding scheme, obtaining ksr2-/- and wild-type male littermates to
use in the behavioral studies was essentially impossible as mice lacking ksr2 expression
often do not survive past weaning. Using an inducible knockout mouse model, we can
properly measure the contribution of KSR2 to anxiolytic phenotypes using littermate
controls.
At the time of these studies, we also conducted assays to measure a potential
depression-related phenotype in the littermate-controlled ksr1-/- mice, including the tail
suspension test (TST) and Porsolt’s forced swim test (FST). These tests were performed
on the same mice as the open field and elevated zero maze. Videos of these tests were
recorded and need to be analyzed by two independent, blinded reviewers for time spent
immobile. However, due to the innate agility of the C57BL/6 strain, the tail suspension
test may not be an appropriate test to measure depression (439). If the data from the
FST are indicative of a depressive phenotype, we may need to utilize a learned
helplessness paradigm to prevent lost data due to tail climbing.
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